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ABSTRACT 
Guihong Qi 
 
Biomarker Discovery in Early Stage Breast Cancer Using Proteomics Technologies 
 
Among women in the United State, breast cancer is the most common cancer 
diagnosed in women with approximately 200,000 new cases reported each year and the 
second leading cause of cancer-related deaths in women, according to the American 
Cancer Society.  Diagnosing breast cancer as early as possible improves the likelihood of 
successful treatment and can save many lives.  However, using mammography as a 
current method to detect breast tumor has intrinsic limitations.  Thus early diagnostic 
biomarkers are critically important for detection, diagnosis, and monitoring disease 
progression in breast cancers. 
 Recently, liquid chromatography (LC) mass spectrometry (MS)-based label-free 
protein quantification method has become a popular tool for biomarker discovery due to 
its high-throughput feature and unlimited sample size for quantitative comparison under 
different biological conditions.  In this study, we applied this technology with inclusion 
of statistical analysis to detect the protein differential expression levels in the plasma 
samples from the early-stage breast cancer patients.  With a combined protein 
classification and pathway analysis, a panel of potential protein biomarkers has been 
identified. 
 The results from this study showed that LC/MS-based label-free protein 
quantification technology along with bioinformatics analysis provides an excellent 
 v 
opportunity to help determine biomarker candidates for future validation studies and 
development of new strategies for early diagnostics and disease treatment. 
 
Mu Wang, Ph.D., Committee Chair 
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1. Introduction 
Breast cancer is the most common type of solid tumor diagnosed in women with 
approximately 200,000 new cases reported each year in the United States.  In 2007, more 
than 40,000 women died of breast cancer in the United States, making it the second 
leading cause of cancer-related deaths in women [1].  The chance of developing invasive 
breast cancer at some point in a woman’s life is about 1 in 8.  The chance that breast 
cancer will be responsible for a woman’s death is about 1/35 [2].  Breast cancer was one 
of the first malignancies for which targeted therapy was used to treat a subgroup of the 
affected population [3].  Diagnosing breast cancer as early as possible improves the 
likelihood of successful treatment [4], and breast cancer survivors are now the largest 
group of cancer survivors in the United States [5, 6].  Early detection and prevention of 
this disease is urgently needed because many patients succumb to advanced diseases as 
the primary tumor metastasizes to other organs.  It is evident that early detection for 
breast cancer can save many lives [7].  
Current methods used to detect breast tumors, either benign or malignant, are 
primarily based on mammography.  However, there are intrinsic limitations to 
mammography as only 63% of breast cancers are localized at the time of diagnosis [3].  
Small lesions are frequently missed and may not be visible, particularly in young women 
with dense breast tissue [8].  For a breast tumor to be detected in mammography, it must 
be at least a few millimeters in size.  Unfortunately, a tumor of this size already contains 
several hundred million cells.  From the cellular point of view, given the fact that a single 
cell can lead to the development of a whole tumor, it is already at a late stage when a 
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tumor is detected by mammography [9].  Third, mammograms have a high rate of false 
positives, which will result in costly and invasive follow-up tests, including biopsies, of 
which 75% prove benign [10].  Also, there are distinct subgroups of breast cancer for 
which specific biological targets have not yet been identified [11].  Biomarkers are 
critically important tools for detection, diagnosis, treatment, monitoring, and prognosis.  
Biomarkers are biological molecules that are indicators of physiological state and also of 
change during a disease process [12].  The value of a biomarker lies in its ability to 
provide an early indication of the disease and to monitor disease progression.  
The primary goal of this study is to discover potential protein biomarker 
candidates using early stage breast cancer patient samples and provide valuable 
information for biomarker validation studies, thus developing new strategies for early 
detection, diagnostics, disease monitoring, and therapeutic treatment.  In the previous 
studies, some potential biomarkers of breast cancer have been suggested [4, 13, and 14].  
As these were identified using one-protein-at-a-time approaches, they may or may not be 
true biomarkers of breast cancer.  It is believed that biomarkers are more influential as a 
panel of proteins within a biological sample—there seems to be a growing consensus that 
a panel of markers may be able to supply the specificity and sensitivity that individual 
markers lack [14, 15].  Thus, measurement of multiple proteins in a single assay may give 
a better and more complete picture of what is happening at the protein expression level 
that is associated with the disease.  In addition, under diseased conditions, it is beneficial 
to be able to look at multiple proteins to develop a greater understanding of the disease 
and how it affects life. 
  
 
 
        3 
Proteomics has become the most powerful and efficient methodology in recent 
years for simultaneous analysis of thousands of proteins on the basis of differences in 
their expression levels and post-translational modifications involved in cancer 
progression [16].  Currently, there is no common consensus within the field as to which 
proteomic technology can attain complete and quantitative protein coverage of all 
proteins in a biological sample. 
The most commonly used proteomic approach is accomplished by a combination 
of either two-dimensional gel electrophoresis (2DE) or liquid chromatography (LC) to 
separate and visualize proteins/peptides and mass spectrometry (MS) to identify, 
characterize, and quantify them.  2DE has been the workhorse of proteomics for the past 
decade and is still one of the most widely used tools for separating proteins [17], but its 
biggest disadvantage is the inability to cover the dynamic range of proteins in a 
proteome.  One alternative strategy to partially overcome the disadvantage of 2DE is 
LC/MS-based technology, primarily stable isotopic labeling technology coupled with 
MS.  Although some successes using this technology for protein quantification have been 
reported [18], it is not always practical and has several disadvantages.  For example, 
labeling with stable isotopes is expensive and the isotopic labels sometimes exhibit 
chromatography shifts that can make quantification of differentially labeled peptides 
computationally difficult [19].  Moreover there may not be enough different isotopes to 
allow for simultaneous quantification of proteins from multiple samples (i.e., >8 groups) 
[19], and it remains technically challenging to characterize the global proteome due to the 
fact that proteins without cysteine residues cannot be labeled. 
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 More recently, LC/MS-based label-free protein quantification has gradually 
gained its popularity due to its high-throughput feature and unlimited sample size for 
quantitative comparison under different biological conditions.  It uses extracted ion 
chromatograms (XICs) from mass spectrometric analysis for relative quantitation of 
protein expression [16, 20, 21, and 22]. 
The focus of this project is to use the label-free protein quantification platform to 
compare plasma proteins from early stage (stage I and stage II) breast cancer patients in 
order to identify biomarkers for early detection of breast cancer.  Using a large sample set 
(80-sample) will not only allow us to identify potential breast cancer biomarker 
candidates, but also establish an optimized platform and protocol for biomarker 
discoveries.  Information obtained from this study will also help to determine biomarker 
candidates for future validation studies and development of new strategies for diagnostics 
and disease treatment.  
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2. Materials and Methods 
2.1 Human Plasma Samples 
Forty plasma samples from women with breast cancer and 40 plasma samples 
from healthy age-matched volunteer women (control) were collected by the Hoosier 
Oncology Group (HOG) (Indianapolis, IN, USA).  All patients involved in this study 
were diagnosed with a stage II or earlier breast cancer.  Details of these patients are 
shown in Table 1.  
2.2. Experimental Designs  
The study is consisted of two groups of plasma samples, 40 plasma samples from 
women with stage I or II breast cancer (all prior to chemotherapy) and 40 plasma samples 
from healthy age-matched women to serve as controls.  Single injections for each sample 
were performed.  The tables shown below summarize the patient information and the 
experimental design. 
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Table 1: Summary for 80 samples based on age ranges    
 
 
 
 
 
 
 
 
 
*INV: invasive; DCIS: ductal carcinoma in situ 
Table 2: Experimental Design 
Group Condition Number of Samples Number of Injections 
0H Healthy 40 40 
1C Cancer 40 40 
 
2.3 Materials 
Ammonium carbonate, ammonium bicarbonate, urea, formic acid, lysozyme, 2-
Iodoethanol, and triethylphosphine were all purchased from Sigma-Aldrich (St. Louis, 
MO, USA).  Acetonitrile and MS grade water were purchased from Honey Burdick & 
Jackson (Morristown, NJ, USA).  Trypsin was purchased from Worthington Biochemical 
Corporation (Lakewood, NJ, USA).  Seppro tip IgY-12 and reagent kit were purchased 
Age Distribution 30-39 40-65 > 65
Cancer Healthy Cancer Healthy Cancer Healthy
Number
of patients
3 3 29 34 8 3
Race 3-White 1 28-White 31 8-White 3
0-Black 1 1-Black 3 0-Black
0-Others 1 0-Others 0-Others
Ethnicity 3-Nonhispanic 3 28-Nonhispanic 33 8-Nonhispanic 3
0-Hispanic 1-Hispanic 0-Hispanic
0-Unknown 0-Unknown 1 0-Unknown
Metastasis 3-No 24-No 6-No 
0-Yes 1-Yes 1-Yes 
0-Unknown 4-Unknown 1-Unknown
Cancer Type* 2-INV 12-INV 4-INV 
1-DCIS 10-DCIS 4-DCIS
0-Unknown 7-Unknown 0-Unknown
Tumor Size
(cm)
m = 1.3 
[0.2,1.7]
m = 2.37 
[0,5.5]
m = 1.06 
[0,4.5]
Lymph Node+ 0 10 4
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from GenWay Biotech (San Diego, CA, USA) and HPLC column – Xbridge-C18 (2.1 
mm x 50 mm, pore size = 2.5 µm) was purchased from Waters (Ireland). 
2.4 High Abundant Protein Removal 
A large number of proteins present in blood plasma indicate an excellent 
biospicemen for discovering biomarkers for potential clinical diagnostics and 
therapeutics.  However, low-abundance proteins are often undetectable in proteomic 
analysis of plasma due to the high abundance of some circulating proteins [23].  These 
high-abundance plasma proteins are the main cause of assay background.  For example, 
albumin, the most abundant protein in plasma, constitutes over half of the plasma 
proteins and is present at 30-50 mg/mL concentration.  In contrast, most of the potential 
biomarkers are secreted into the blood stream at very low copy number, especially in the 
early onset of diseases [24, 25].  Thus, removal of the high-abundance proteins is a 
critical step in biomarker discovery.  In this study, we used the GenWay Seppro Tip IgY-
12 and PSS Bio Instrument’s automated Magtration System 12 GC to remove the top 12 
most abundant proteins in plasma.  Our data showed that the GenWay Seppro Tip IgY-12 
system has both efficiency and reproducibility required for biomarker discovery when 
compared with several other commercially available abundant protein removal kits, 
including Montage (Millipore) and Multiple Affinity Removal System (Agilent).  The 
performance of this Tip IgY-12 also has been reported to be specific, efficient, and 
reproducible in a previous study [23].  The Seppro Tip IgY-12 is packed with 
immobilized IgY antibody beads for immunoaffinity capture of human albumin, IgG, α1-
antitrypsin, IgA, IgM, Transferrin, Haptoglobin, α1-acid glycoprotein, α2-Macroglobulin, 
HDL (Apolipoprotein A1 & AІІ), and Fibrinogen [26].  After the high abundant proteins 
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removal, the low abundant proteins in the flow-through fractions were analyzed.  The 
Seppro Tip products are designed to be used with PSS Bio Instrument’s automated 
Magtration System 12GC.  Twelve tips are simultaneously operated to process twelve 
samples at once.  Specific removal of 12 high-abundance proteins depletes approximately 
95% of total protein mass from human plasma [26].  
For this study, 80 human plasma samples were centrifuged at 10,000 rpm for 1 
minute to remove insoluble material, and the clear supernatant was used for downstream 
processing.  Briefly, 15 µL clear human plasma samples were diluted with TBS buffer 
(10 mM Tris-HCl, 0.15 M NaCl, pH 7.4) to a final volume of 500 µL in a 1.5 mL screw-
cap tube.  The sample containing tubes, eluting buffer tubes (0.25 M Glycine-HCl, pH 
2.5), washing buffer tubes (TBS, 10 mM Tris-HCl, 0.15 M NaCl, pH 7.4), neutralization 
buffer tubes (0.25 M Tris-HCl, pH 8.0) and depletion tips were all loaded on the PSS Bio 
Instrument’s automated Magtration System 12GC before the depletion protocol started.  
The flow-through (depleted) fractions were collected, and the bound fractions containing 
high abundant proteins can be recovered with elution buffer if desired.  The column was 
then washed with washing buffer and re-equilibrated with neutralization buffer for 
application of subsequent samples.  This column can be reused for 25 cycles. 
2.5 Protein Reduction, Alkylation and Digestion 
The protein concentration of the collected flow-through fractions were determined 
by the Bradford protein assay [33].  The collected flow-through fractions were then 
concentrated to about 30 µL from 500 µL with a spin concentrator (Barnstead/Genevac, 
Genevac LTD, IPSwich England) and spiked with 0.15 µg chicken lysozyme (which was 
used as internal standard for QA/QC purpose).  30 µL of 8 M urea, 25 µL of water, and 5 
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µL of 1 M ammonium carbonate, pH 11.0, were then added to the depleted plasma 
samples.  Next, an equal volume (80 µL) of reduction/alkylation cocktail (2% 
iodoethanol, and 0.5% triethylphosphine in acetonitrile) was added [27].  The solutions 
were capped and incubated for 1.5 hrs at 37оC, after which it was dried overnight using a 
speed-vacuum.  The pellet was then dissolved in 150 µL of a trypsin solution (0.6 µg 
trypsin in 100 mM ammonium bicarbonate, pH 8.0) to produce a final concentration of 
1.6 M urea solution.  The digestion was carried out at 37оC overnight.  100 µL (20 µg) of 
this digest was then injected onto a Surveyor HPLC system coupled with an LTQ mass 
spectrometer [Thermo-Fisher Scientific, Waltham, MA, USA] in a random order. 
2.6 Mass Spectrometry Instrumentation  
All tryptic digests were separated by an XBridge (2 mm x 50 mm) C-18 reversed 
phase column (Waters, Milford, MA, USA) at a flow rate of 200 µL/min.  The linear 
gradient conditions for elution of peptide were 10-95% of 0.1% formic acid in 50% 
acetonitrile (Buffer B) over 120 min, followed by 5 min at 100% of 0.1% formic acid in 
80% acetonitrile (Buffer C), then followed by 90% of 0.1% formic acid in water (Buffer 
A) and held for 17 min.  Between each sample in the set an injection of water is made and 
a shortened (60 min) gradient is performed to reduce carryover.  The effluent from HPLC 
column was directly electro-sprayed into the LTQ mass spectrometer.  The LTQ was 
performed in positive ion mode with 4.8 kV electrospray potential, a sheath gas flow of 
20 arbitrary units, and a capillary temperature of 225oC.  The source lenses were set by 
maximizing the ion current for the M+2H+ charge state of angiotensin and data were 
collected in triple-play mode (MS scan, Zoom scan, and MS/MS scan) with m/z range of 
350-2000 amu. 
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2.7 Peptide and Protein Identification  
All data collected from triple-play experiment were used to estimate the quality of 
subsequent monoisotopic and average mass of the peptide, the charge state, and MS/MS 
spectra of the peptide (shown in Figure 2.7.1).  Protein identification was carried out 
using the software package licensed from Eli Lilly and Company [20].  To minimize 
false-positive identifications, the low quality data were filtered out by the same software 
package [20].  Briefly, filtered data were subsequently searched against the IPI 
(International Protein Index) and the Non-Redundant (NCBI) databases using both the 
SEQUEST and X!Tandem algorithms.  Proteins identified by SEQUEST and X!Tandem 
are categorized into priority groups based on the quality of the protein identification as 
shown in Table 3.  The Peptide ID confidence assigns a protein to a ‘HIGH’ or 
‘MODERATE’ classification based on the peptide with the highest peptide ID 
Confidence (the best peptide).  Proteins whose best peptide has a confidence between 90-
100% are assigned to the ‘HIGH’ category regardless of whether there are other peptides 
having low confidence.  Proteins whose best peptide has a confidence between 75-89% 
are assigned to the ‘MODERATE’ category.  All peptides with confidence less than 75% 
are filtered out by the software before further analysis.  To confirm protein identification, 
each database search result was then searched against a reverse database.  If any MS/MS 
spectra were matched against the reverse database, it was then excluded from the list.       
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Table 3: Classification of protein identification 
Protein Peptide ID Multiple Unique 
Priority Confidence Sequences 
1 High (90-99%) Yes 
2 High (90-99%) No 
3 Moderate (75-89%) Yes 
4 Moderate (75-89%) No 
 
The confidence in protein identification increases with the number of distinct 
amino acid sequences identified.  Therefore proteins are also categorized depending on 
whether only one or multiple unique peptide sequences are obtained.  A protein is 
classified as ‘YES’ in the ‘Multiple Sequences’ column if it has at least two distinct 
amino acid sequences with the required ID confidence; otherwise it is classified as ‘NO’.  
Priority assignments reflect the level of confidence in the protein identification.  Priority 
1 proteins would have the highest likelihood of correct identification and Priority 4 
proteins the lowest.  This priority system is based on the quality of the amino acid 
sequence identification (Peptide ID Confidence) and whether one or more sequences are 
identified (Multiple Sequences).  We typically view any protein identification outside of 
priority 1 as questionable [29].  All data processing is carried out on a Linux cluster using 
highly parallel processing and data qualification and filtering software.  
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Figure 2.7.1 The triple-play experiment for label-free protein quantification 
2.8 Peptide and Protein Quantification 
Protein quantification was also carried out using the same software package we 
licensed from Lilly as described earlier [20].  Briefly, once the raw files are acquired 
from the LTQ, all extracted ion chromatograms (XIC) are aligned by retention time 
(Figure. 2.8.1).  To be used in the protein quantification procedure, each aligned peak 
must match parent ion, charge state, daughter ions (MS/MS data) and retention time.  
After alignment, the area-under-the-curves (AUC) for individually aligned peaks from 
identified peptides from each sample are computed; the AUCs are then compared for 
relative protein abundance.   
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One of the key features of the algorithm for protein quantification is the 
chromatographic peak alignment, because large biomarker studies can produce 
chromatographic shifts due to multiple injections of the samples onto the same HPLC 
column.  Un-aligned peak comparison will result in larger variability and inaccuracy in 
peptide quantification [20].  A graphical example of a comparison of peptide quantities 
across a complex biological sample is shown in Figure. 2.8.1. All peak intensities are 
transformed to a log2 scale before quantile normalization [28].  Quantile normalization is 
a method of normalization that essentially ensures that every sample has a peptide 
intensity histogram of the same scale, location, and shape.  This normalization procedure 
removes trends introduced by sample handling, sample preparation, total protein 
differences, and changes in instrument sensitivity while running multiple samples.  If 
multiple peptides have the same protein identification, then their quantile normalized log2 
intensities are averaged to obtain log2 protein intensities.  The log2 protein intensity is the 
final quantity that is statistically modeled.  A separate model is fit for each protein.  The 
appropriate model depends on the phenotype associated with the protein expression.  
Phenotypes with categorical response would probably be studied with an ANOVA model 
whereas phenotypes with numerical response would be studied with a regression model.  
Significance is first measured by a p-value.  All p-values are then adjusted to control for 
the False Discovery Rate (FDR).  The FDR is estimated by the q-value which is an 
adjusted p-value.  The FDR is the proportion of significant changes that are false 
positives.  If proteins with a q-value ≤ 0.05 are declared significant, it is expected that 5% 
of the declared changes will be false positives.  A data processing flow chart is shown in  
Figure. 2.8.2. 
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Figure 2.8.1 Peptide quantification by extracted ion chromatograms (XICs).  Panels A 
and B are total ion chromatograms (TICs) from treated and control sample respectively.  
Panels C and D are extracted ion chromatograms (XICs) from treated and control 
samples.  The area-under-the-curve (AUC) can be calculated and compared for the 
relative quantity of the peptide of interest (indicated by arrows), thus protein of interest. 
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Data 
Filtering
Quantification
Figure 2.8.2 Data processing flow chart 
2.9 Quality Assurance and Quality Control 
In this experiment, all of the samples were prepared by the same person.  All 
injections were randomized and performed using the same C18 microbore column.  All 
buffers were prepared at the same time for all injections.  To assess the stability of the 
column and instrument, the same amount of chicken lysozyme was spiked into every 
sample before tryptic digestion.  The spiked internal standard chicken lysozyme can help 
check ion intensities before and after normalization and served as a QA/QC standard.  In 
the plot shown in Figure 2.9.1, the individual protein quantities (peak intensities) are 
displayed for each injection.  The overall mean for each group is displayed by the line 
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across the plot.  Since a constant amount of chicken lysozyme was spiked into the entire 
sample, it should show no significant changes between groups.  If there is a significant 
group change then it is advisable to be cautious when interpreting significant changes in 
other proteins with smaller fold changes.  
Lo
g2
(In
te
ns
ity
)
15.3
15.4
15.5
15.6
15.7
15.8
15.9
16.0
16.1
16.2
H
03
2
H
53
6
H
53
7
H
53
8
H
55
0
H
55
3
H
55
7
H
56
4
H
57
5
H
58
2
H
58
3
H
58
5
H
59
3
H
59
4
H
59
8
H
59
9
H
60
0
H
60
4
H
60
5
H
61
0
H
61
5
H
62
1
H
62
2
H
62
3
H
62
5
H
62
8
H
62
9
H
63
1
H
63
3
H
64
7
H
66
1
H
66
5
H
69
6
H
70
0
H
71
0
H
72
2
H
72
4
H
73
5
H
73
9
H
74
8
C0
01
C0
02
C0
04
C0
06
C0
07
C0
08
C0
09
C0
10
C0
11
C0
12
C0
13
C0
16
C0
17
C0
18
C0
19
C0
20
C0
21
C0
22
C0
23
C0
24
C0
25
C0
26
C0
27
C0
28
C0
29
C0
30
C0
31
C0
32
C0
36
C0
37
C0
39
C0
40
C0
41
C0
43
C0
44
C0
45
C0
46
C0
48
C0
49
C0
51
0H 1C
sample w ithin group
 
Figure 2.9.1 The individual protein intensities for chicken lysozyme are plotted on a log2 
scale.  The overall mean for each group is displayed by the line across the plot. 
2.10. Pathway Analysis 
After the proteins with significant changes between breast cancer and normal 
control were identified by the LC/MS-based quantitative analysis, the pathway analysis 
was performed using Pathway Studio™ software (5.0, Ariadne Genomics, Rockville, MD, 
USA).  The differentially expressed proteins were run against the ResNet database that 
was equipped with functional relationships from other scientific literature and 
commercial databases.  The filters we used included “all shortest paths between selected 
entities” and “cell process”.  Protein interactions and their biological processes were 
reviewed.  A list of proteins of interest was generated from this information, including 
their pathways and functions. 
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3. Results 
3.1 Protein Identification  
In this study, with analysis of 40 plasma samples from breast cancer patients and 
40 plasma samples from healthy controls, a total of 1422 proteins and 6457 peptides were 
identified and quantified (summarized in Table 4).  
Of these, 501 proteins were identified with high confidence (priority 1 and 2), 
and 385 proteins showed a significant expression change between cancer patient and 
healthy control (false discovery rate less than 5%).  The median %CV for priority 1 
protein was 14.24% (technical plus biological variations), and the overall Median %CV 
for all proteins was 19.42%.  Among the 921 proteins that were less confidently 
identified (Priorities 3 and 4), there were also 251 proteins that had significant changes. 
Table 4: Summary information of the study using LC/MS-based label free protein 
quantification method 
Protein Peptide ID Multiple Number Number Maximum Median %CV 
Priority Confidence Sequences of Proteins Significant Absolute sample 
    Changes Fold-change  
1 High Yes 222 58 1.4 14.2 
2 High No 279 76 1.4 20.1 
3 Moderate Yes 53 13 1.2 14.3 
4 Moderate No 868 238 1.5 20.7 
Overall   1422 385 1.5 19.4 
 
3.2 Protein Quantification 
For protein quantification, every peptide quantified had an intensity measurement 
for each sample.  The intensity measurement is a relative quantity giving the AUC from 
the extracted ion chromatogram (XIC) after background noise removal.  The AUC was 
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measured at the same retention time for each sample after the sample chromatograms had 
been aligned [20].  The example alignment result of this study is shown in Figure 3.2.1.  
The intensities were then transformed to the log scale and quantile normalized [28].  If 
multiple peptides had the same protein identification then their quantile normalized log 
base 2 intensities were averaged to obtain log base 2 protein intensities.  The log base 2 
protein intensity is the final quantity that is fit by a separate Analysis of Variance 
(ANOVA) statistical model for each protein.  Figure 3.2.2 shows an example of relative 
protein expression levels when comparing cancer sample group with control sample 
group. 
 
Figure 3.2.1 The extracted ion chromatograms (XIC) is aligned among all samples in the 
study and a selected reference sample in the study by retention time.  To be used in the 
protein quantification procedure, each aligned peak between the two samples must match 
parent ion, daughter ion, and charge state and the retention time.  A time shifting function 
puts the samples on the same time scale (in 1 min). 
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Annotation=Alpha-2-HS-glycoprotein_precursor
Rank=2, protein ID=225766 
Annotation=Alpha_antitrypsion
Variability chart for mean Log2 (intensity) =/- Stderr
Rank=1, protein ID=IPI00022431 
Annotation=Alpha-2-HS-glycoprotein_precursor
Variability chart for mean Log2 (intensity) =/- Stderr
Figure 3.2.2 Example of relative protein expression levels under different conditions.  
The intensities which are given by the AUC from the XIC are transformed to the log base 
2 scale; base 2 is popular because a two-fold change is transformed to a unit change on a 
log base 2 scale.  Error bars show standard errors based on the ANOVA model.  Rank is 
assigned by sorting all the proteins in the order of significant change (Yes, No), priority 
(1-4), and q value. 
3.3 Analysis 
A significant fold change between groups is based on controlling the false 
discovery rate (FDR) at less than 5%.  The FDR is estimated by the q-value which is an 
adjusted p-value.  The FDR is the proportion of significant changes that are false 
positives.  If proteins with a q-value less than 5% are declared significant, that means the 
chance of false positives are less than 5%.  Because protein intensity is on a log base 2 
  
 
 
        20 
scales, the group means and their differences are converted to arithmetic means and fold 
change as calculated below:  
T = Cancer group average of log base 2 scale protein intensities 
C = Health control group average of base 2 protein intensities 
Fold change = Mean_T / Mean _C when Mean_T ≥ Mean_C (up-regulation) 
Fold change = - Mean_C / Mean_T when Mean_C > Mean_T (down-regulation) 
Fold change = 1 shows no change 
3.4 Genome Ontology Classification of the Detected Proteins with Significant 
Changes 
All proteins (priority 1-4) with significant changes (q < 0.05) were annotated and 
categorized based on their biological function, molecular function, and cellular 
component with Gene Ontology [31, 32].  Figures 3.4.1, 3.4.2, and 3.4.3 present all 
proteins with significant changes that were presented in the form of a pie chart.  In order 
to keep the graph less cluttered, only a few of the top ranking ones are included in the pie 
chart.  The next three graphs in Figures 3.4.4, 3.4.5, and 3.4.6, respectively, are for fold-
change comparison between groups 0H and 1C.  The data we obtained by LC/MS label-
free quantification method is graphed to show a better picture of up- and down-
regulations of the different proteins with respect to their biological process, molecular 
functions, and cellular locations.  Positive columns represent the number of proteins 
which are up-regulated in the first group (0H) as compared to the second group (1C) 
(fold-change value is positive).  Negative columns represent the number of proteins 
which are down-regulated in the first group as compared to the second group (fold-
change value is negative) 
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Figure 3.4.1 Cellular Component GO term 
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Figure 3.4.2 Biological Process GO terms 
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Figure 3.4.3 Molecular Function GO term 
• The above three pie charts are for the protein classification with Gene Ontology 
(GO). 
• All proteins with significant changes were categorized based on their biological 
function, molecular function, and cellular component with GO. 
• In order to keep the graph less cluttered, only a few of the top ranking proteins are 
included in the pie chart. 
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Figure 3.4.4 Classification based on GO Term: Cellular Component 
 
 
Figure 3.4.5 Classification based on GO Term: Biological Process 
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Figure 3.4.6 Classification based on GO Term: Molecular Function 
• The above three graphs are for Fold Change comparison between groups 0H and 
1C. 
• All proteins with significant change were selected. 
• Positive column represents the number of proteins which are up regulated in the 
first group (Healthy) compared with second group (Cancer) (fold change value is 
positive). 
• Negative column represents the number of proteins which are down regulated in 
the first group compared with second group (fold change value is negatively). 
3.5 Comparison with a List of Candidate Cancer Biomarkers 
 
We compared the proteins with significant changes from our data against a list of 
previously published 1261 candidate cancer biomarkers [14], of which 22 proteins were 
overlapped (shown in Table 5).  A list of 1261 proteins believed to be differentially 
expressed in human cancer has been compiled from literature and other sources.  These 
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proteins, only some of which have been detected in human plasma, represent a population 
of candidate plasma biomarkers that could be useful in early cancer detection and 
monitoring given sufficiently sensitive and specific assays.  Most of them have been 
detected in studies of tissue or nuclear components (tissue, DNA, or RNA).  Among these 
candidates, only few have been validated and approved [14].  This list of cancer 
biomarkers are only the candidates which were provided for future validation.   
Table 5: 22 proteins with significant changes which also present in the published list of 
cancer biomarker  
Gene name Annotation Function 
AHSG Alpha-2-HS-
glycoprotein_precursor 
Function: Promotes endocytosis, possesses opsonic 
properties and influences the mineral phase of bone. 
Shows affinity for calcium and barium ions.  
APOA2 Apolipoprotein Function: May stabilize HDL (high density lipoprotein) 
structure by its association with lipids, and affect the 
HDL metabolism.  
SERPINA3 Isoform_2_of_Alpha-1-
antichymotrypsin_precursor 
Function: Although its physiological function is 
unclear, it can inhibit neutrophil cathepsin G and mast 
cell chymase, both of which can convert angiotensin-1 
to the active angiotensin-2.  
 Alpha-1-
antitrypsin_precursor 
Function: Inhibitor of serine proteases. Its primary 
target is elastase, but it also has a moderate affinity for 
plasmin and thrombin. The aberrant form inhibits 
insulin-induced NO synthesis in platelets, decreases 
coagulation time and has proteolytic activity agaisnt 
insulin and plasmin.  
FINC Isoform_1_of_Fibronectin_
precursor 
Function: Fibronectins bind cell surfaces and various 
compounds including collagen, fibrin, heparin, DNA, 
and actin. Fibronectins are involved in cell adhesion, 
cell motility, opsonization, wound healing, and 
maintenance of cell shape. Interaction with TNR 
mediates inhibition of cell adhesion and neurite 
outgrowth (By similarity).  
PLG Plasminogen_precursor Function: Angiostatin is an angiogenesis inhibitor that 
blocks neovascularization and growth of experimental 
primary and metastatic tumors in vivo.  
C7 complement_C7_[Homo_sa
piens] 
Function: C7 is a constituent of the membrane attack 
complex. C7 binds to C5b forming the C5b-7 complex, 
where it serves as a membrane anchor.  
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ORM1 Alpha-1-
acid_glycoprotein_1_precur
sor 
Function: Appears to function in modulating the 
activity of the immune system during the acute-phase 
reaction.  
C6 complement_component_6
_[Homo_sapiens] 
Function: Involved in the formation of the lytic C5b-
9m complex.  
IGF2 Isoform_1_of_Insulin-
like_growth_factor_II_prec
ursor 
Function: The insulin-like growth factors possess 
growth-promoting activity. In vitro, they are potent 
mitogens for cultured cells. IGF-II is influenced by 
placental lactogen and may play a role in fetal 
development.  
SERPINF1 Pigment_epithelium-
derived_factor_precursor 
Function: Neurotrophic protein; induces extensive 
neuronal differentiation in retinoblastoma cells. Potent 
inhibitor of angiogenesis. As it does not undergo the S 
(stressed) to R (relaxed) conformational transition 
characteristic of active serpins, it exhibits no serine 
protease inhibitory activity.  
S100A9 Protein_S100-A9 Function: Expressed by macrophages in acutely 
inflammated tissues and in chronic inflammations. 
Seem to be an inhibitor of protein kinases. Also 
expressed in epithelial cells constitutively or induced 
during dermatoses. May interact with components of 
the intermediate filaments in monocytes and epithelial 
cells.  
SAA1 SAA1_protein_[Homo_sapi
ens] 
Function: Major acute phase reactant. Apolipoprotein 
of the HDL complex.  
VIL1 Villin-1 Function: Ca (2+)-regulated actin-binding protein.  
XRCC1 DNA-
repair_protein_XRCC1 
Function: Corrects defective DNA strand-break repair 
and sister chromatid exchange following treatment with 
ionizing radiation and alkylating agents.  
TXLNA hypothetical_protein_[Hom
o_sapiens] 
Function: May be involved in intracellular vesicle 
traffic and potentially in calcium-dependent exocytosis 
in neuroendocrine cells.  
BIRC6 Baculoviral_IAP_repeat-
containing_protein_6 
Function: May protect cells from undergoing apoptosis.  
COL11A1 Isoform_B_of_Collagen_al
pha-1(XI)_chain_precursor 
Function: May play an important role in fibrillogenesis 
by controlling lateral growth of collagen II fibrils.  
NAIP Baculoviral_IAP_repeat-
containing_protein_1 
Function: Prevents motor-neuron apoptosis induced by 
a variety of signals.  
ANXA11 Annexin_A11 No annotated function present  
ITGA5 Integrin_alpha-5_precursor Function: Integrin alpha-5/beta-1 is a receptor for 
fibronectin and fibrinogen. It recognizes the sequence 
R-G-D in its ligands. In case of HIV-1 infection, the 
interaction with extracellular viral Tat protein seems to 
enhance angiogenesis in Kaposi's sarcoma lesions.  
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FADD FADD_protein Function: Apoptotic adaptor molecule that recruits 
caspase-8 or caspase-10 to the activated Fas (CD95) or 
TNFR-1 receptors. The resulting aggregate called the 
death-inducing signaling complex (DISC) performs 
caspase-8 proteolytic activation. Active caspase-8 
initiates the subsequent cascade of caspases mediating 
apoptosis.  
 
3.6 Pathway Analysis 
385 proteins with significant changes from LC/MS data were analyzed using 
Pathway Studio™ 5.0.  A corresponding gene list was created from these proteins.  This 
software was developed to navigate and analyze biological pathways, gene regulation 
networks and find relationships among genes, proteins, cell processes, and diseases from 
a dataset.  Several proteins were selected based on our data from LC/MS and information 
obtained from the pathway analysis and other literature searches, which may serve as a 
panel of biomarker candidates in early stage of breast cancer. 
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ORM1
 
 
 
 
Figure 3.6.1 Pathway Analysis 1: A suggested protein network involving early stage 
breast cancer, the gene list was run against the ResNet database.  The filters were set up 
including “all shortest paths between selected entities” and “proteins with direct 
regulation.”  A few lines were selected for estimating the breast cancer biomarker 
candidates. 
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Line 1: ITGA5 → FN1 → IGFBP3 → IGF → TP53 → Breast Cancer 
Line 2: SHC1 → IGF → TP53 → Breast Cancer 
Line 3: TP53 → ESR1 → TSC2 → Breast Cancer 
Line 4: ORM1→PLG → IGFBP3 → IGF → TP53 → Breast Cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.2 Pathway Analysis 2: A suggested protein network involving early stage 
breast cancer, the gene list was run against the ResNet database.  The filters were set up 
including “all shortest paths between selected entities” and “cell process.”  The functions 
of the main genes are marked.  
Table 6 below shows the proposed biomarker candidates in the early stage breast cancer 
found by us and they are supported by the pathway analysis and literature search.  Among 
SHC1
Positive regulation of 
mitosis
A mitogenic
grow factor
Positive regulation 
of apoptosis
Cell adhesion
Anti tumor 
metastasis
Tumor suppressor
Anti cancer 
metastasis
Induction of apoptosis
ORM protecting tumor cells against 
immunological attack 
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them, IGF2, ITGA5, C7, PLG, and TSC2 were also found in the Cancer Biomarker List 
[14] which is the data that was compared in the chapter 3.5.  FBLN1 and FN1 were 
presented in the biomarker protein list that was provided by Clinical Proteomic 
Technology Assessment for Cancer (CPTAC) Program [30]. 
Table 6: The candidate biomarkers in early stage breast cancer found by pathway analysis 
and literature search 
 
Gene Annotation Function Notes FC 
IGF2 Insulin-like growth 
factor 2 
Function: The insulin-
like growth factors 
possess growth-
promoting activity. In 
vitro, they are potent 
mitogens for cultured 
cells. IGF-II is 
influenced by 
placental lactogen and 
may play a role in 
fetal development.  
A mitogenic growth 
factor; may have a role 
in fetal development. 
Increase in breast, 
prostate, lung and 
colorectum cancer. 
1.08 
IGFBP3 Insulin-like growth 
factor binding protein  
Function: an insulin 
growth factor binding 
protein; involved in 
modulating IGF 
action. 
Positive regulation of 
apoptosis, regulation of 
cell growth, positive 
regulation of myoblast 
differentiation, 
negative regulation of 
signal transduction. 
Increase in breast, 
prostate, lung and 
colorectum cancer. 
1.14 
SHC1* src homology 2 
domain-containing 
transforming protein 
C1 
Key mediators of the 
insulin-like growth 
factor pathway, 
involved in 
transformation and 
differentiation in a 
Ras-dependent 
fashion. 
Regulation of 
epidermal growth 
factor receptor activity; 
positive regulation of 
mitosis; positive 
regulation of cell 
proliferation and 
activation of MAPK 
activity. Actived in a 
high number of human 
tumors, including 
breast tumors.     
1.22 
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FBLN1 fibulin 1 Function: 
Incorporated into 
fibronectin-containing 
matrix fibers. May 
play a role in cell 
adhesion and 
migration along 
protein fibers within 
the extracellular 
matrix (ECM). Could 
be important for 
certain 
developmental.  
A secreted calcium-
binding glycoprotein. 
Tumor suppressor. 
Altered expression of 
fibulin is associated 
with progression of 
several cancer types: 
bladder cancer breast 
cancer.  
-1.06 
FN1* fibronectin 1 Function: 
Fibronectins bind cell 
surfaces and various 
compounds including 
collagen, fibrnin, 
heparin, DNA, and 
actin. Fibronectins are 
involved in cell 
adhesion, cell 
motility, opsoniztion, 
wound healing, and 
maintenance of cell 
shape. 
Extracellular matrix 
component may play a 
role in fibrosis and anti 
tumor metastasis. It has 
been found to be 
regulated in prostate, 
thyroid and breast and 
ovarian cancer. 
-1.23 
ITGA5 integrin alph5 Function: Integrin 
alpha-5/beta-1 is a 
receptor for 
fibronectin and 
fibrinogen. It 
recognizes the 
sequence R-G-D in its 
ligands. In case of 
HIV-1 infection, the 
interaction with 
extracellular viral Tat 
protein seems to 
enhance angiogenesis 
in Kaposi's sar 
Cell adhesion, integrin-
mediated signaling 
pathway, cell-substrate 
junction assembly, 
alpha subunit that 
interacts with beta 1 
subunit form a 
fibronectin receptor. 
-1.14 
C7,C5, 
C6 and 
C9 
complement 
component 
Function: C7 is a 
constituent of the 
membrane attack 
complex. C7 binds to 
C5b forming the C5b-
7 complex, where it 
serves as a membrane 
anchor. 
Component of 
membrane attack 
complex of 
complement, play a 
role in induction of 
apoptosis. Increase in 
lung cancer patient. 
1.11 
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PLG plasminogen Function: Angiostatin 
is an angiogenesis 
inhibitor that blocks 
neovascularization 
and growth of 
experimental primary 
and metastatic tumors 
in vivo. 
A tumor suppressor 
decreased in stomach 
and colonic cancer. 
-1.06 
ORM1* Alpha-1-acid-
glycoprotein1 
Appears to function in 
modulating the 
activity of the 
immune system 
during the acute phase 
reaction and secreted 
ORM and other acute-
phase reactants may act 
as blocking factors 
protecting tumor cells 
against immunological 
attack, thereby 
contributing to the 
'immune escape' of the 
tumor 
1.36 
TSC2 Isoform_1_of_Tuberin Function: Implicated 
as a tumor suppressor. 
May have a function 
in vesicular transport, 
but may also play a 
role in the regulation 
of cell growth arrest 
and in the regulation 
of transcription 
mediated by steroid 
receptors. Interaction 
between TSC1 and 
TSC2 may facilitate 
vesicular docking. 
Specifically 
stimulates the intrinsic 
GTPase activity of the 
Ras-related protein 
RAP1A and RAB5. 
Suggesting a possible 
mechanism for its role 
in regulating cellular 
growth. A mutation in 
TSC2 leads to 
constitutive activation 
of RAP1A in tumors.  
Regulation of 
progression through 
cell cycle and 
endocytosis.      
1.12 
 
*Proteins with fold change over 20%. 
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3.7 Results from subgroup analysis 
Personalized medicine has become the next big wave toward improved drug 
development and patient care.  In this study, the patient samples were very 
heterogeneous, including four different subgroups based on estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) 
expressions.  We therefore re-grouped them and re-analyzed the same data set.  The 
subgroup information is shown in Table 7.  Group P1 represents basal-like tumors type 
(ER-/PR-/HER2-, all negative), group P2 is HER2 positive (ER-/PR-/HER2+), Group P3 
is luminal type A (ER+/PR+/HER2-), and group P4 is luminal type B (ER+/PR-/HER2)   
Four breast cancer subtypes were identified based on immunohistochemical (IHC) 
expression of the ER/PR and HER2 proteins [34].                            
Table 7: Experimental design for subgroup analysis 
Group Condition Number of Samples 
H Healthy 40 
P1 ER-/PR-/HER2- 10 
P2 ER-/PR-/HER2+ 8 
P3 ER+/PR+/HER2- 6 
P4 ER+/PR-/HER± 5 
 
With the analysis of five different groups using 40 plasma samples from healthy 
controls and a total of 29 plasma samples from four different subtypes breast cancer 
patients (the other 11 patients samples were not used for analysis due to missing subtype 
information), we found most of the proteins that show differential expression are 
predominantly observed in Luminal type B (group P4) and Basal type (group P1).  No 
significance changes with Her2+ (group P2) or luminal type A (group P3). All data are 
shown in Appendix 2 through Appendix 4, and summary results of group P1 and P4 are 
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shown in Table 8.  Haptoglobin and S100A8 are two potential candidates suggested 
through this subgroup analysis shown in Table 9. 
Table 8: Summary results of group P1 and P4 
Proteins Numbers Priority 
Significant 
Change Max Absolute Fold. Change 
P1 riched 34 1,2 Yes 2.1 
P4 riched 54 1,2 Yes 2.1 
 
Table 9: Biomarker candidates analyzed by subgrouping 
Rank Protein ID Annotation Max_FC FC_H_P1 FC_H_P4 Function 
1 IPI00641737 Haptoglobin
_precursor 
2.07 1.39 2.07 Haptoglobin is expressed by the 
liver and secreted in plasma. It 
combines with free plasma 
hemoglobin, preventing loss of 
iron through the kidneys and 
protecting the kidneys from 
damage by hemoglobin, while 
making the hemoglobin accessible 
to degradative enzymes. 
28 IPI00007047 Protein_ 
S100_A8 
1.43 1.01 1.43 Calcium binding protein. It is 
made in larger amountw in 
inflammatory diseases such as 
rheumatoid arthritis, and in some 
types of cancer. 
 
With analysis of five different groups, a total of 1388 proteins were identified and 
quantified.  The result from subgroup analysis is summarized in Table 10.  Among the 
identified proteins, 471 were identified with high confidence (priority 1 and 2).  Out of 
the 193 proteins that demonstrated significant changes, 77 were identified with high 
confidence.  The highest fold change among priority 1 and priority 2 proteins was 2.6, 
and the overall maximum absolute fold change was 4.9 when comparing the differential 
expression between four sub-grouped patient samples to healthy controls.   
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Table 10: Overall summary of subgroup analysis 
Protein 
Priority 
Peptide ID 
Confidence 
Multiple 
Sequences 
Number 
of Proteins 
Number 
Significant 
Changes 
Max Absolute 
Foldchange 
Median %CV 
Sample 
1 High Yes 226 46 2.2 15.9 
2 High No 246 31 2.6 24.8 
3 Moderate Yes 49 7 2.0 17.3 
4 Moderate No 867 109 4.9 22.6 
Overall   1388 193 4.9 21.6 
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4. Discussion 
 It is believed that the nature of breast cancer is multi-factorial, a combination of 
several markers will add sensitivity and more specificity to effectively detect and 
diagnose cancer at its early stage.  To look for such a panel of biomarker candidates of 
breast cancer, it requires not only high-throughput technologies, but also bioinformatics 
tools for complex data analysis.  In this study, an LC/MS-based label-free method was 
applied to identify and quantify proteins in human plasma samples from patients with and 
without breast cancer.  Through our analysis (Table 4), 1422 proteins were identified 
with high confidence, and 385 of them had significant changes between breast cancer 
patients and healthy controls.  The many identified proteins provide a great opportunity to 
find novel biomarkers and predictive panels of biomarkers for early stage breast cancer.  
After pathway analysis and literature search (Table 6), 10 proteins were found to be 
related to a diseased state.  However, among these 10 proteins, only 3 (FN1, ORM1, and 
SHC1) showed fold-changes greater than 20%, which is the cutoff for the study’s median 
%CV.  In this study, we considered the proteins whose fold-change was higher than its 
%CV because the fold-change is the ratio of the largest to the smallest protein intensities 
when comparing two groups and the coefficient of variation (CV) is a relative measure of 
sample variability.  The %CV is the standard deviation divided by the mean on a % scale.  
The %CV may be interpreted as a % error.  If a fold-change is less than a %CV change, 
then a fold-change may not represent a true biologically related change.  In this study 
FN1 and ORM1 all are secretory proteins, and SHC1 is normally functioning within cells 
but released into plasma as a result of cell death or damage, which may serve as a panel 
of potential biomarkers. 
  
 
 
        38 
As we know, early detection of breast cancer will improve the treatment and the 
survival rates of breast cancer patients because the ability to treat and cure breast cancer 
directly depends on the ability to detect it at its earliest stage.  In this study, we used 
plasma samples with stages I and II breast cancer and healthy controls.  After the 
analysis, we found a few proteins with significant fold-changes between the two groups, 
but the largest was only 53%.  This is likely a result of low secretion of disease-related 
proteins into plasma during the early stages of breast cancer.  A protein, or most likely a 
set of proteins, that undergoes changes in concentration or structural composition (e.g., 
PTM) as a result of disease or physiological state may occur more often and with greater 
extent during the later stage of cancer progression [16, 18].  The important proteins (such 
as a secretory protein FBLN1) in the signaling pathway, may have very low fold-change 
in this study, and can be misinterpreted. 
The results from subgroup analysis show that all proteins differentially expressed 
between healthy subjects and those who have breast cancer belong to either Basal type-
triple-negative (P1 with worst prognosis) or Luminal type B (P4), but not Her 2+ (P2) or 
Luminal type A (P3) (Table 7).  The fold changes among the subgroups were 
significantly higher than before sub-grouping.  This data is consistent with recent 
literature, which suggests that many malignancies, including breast cancer, can be more 
effectively treated by first dividing the population into subgroups [35].  Pharmaceutical 
companies use these markers from sub-grouping to develop new drugs more efficiently 
[36].  The drugs are not only more successful at treating patients, but responses to these 
drugs are more predictable as well [36].  For example, the expressions of ER, PR and 
HER2 have been used clinically as predictors of trastuzumab response and hormonal 
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treatment for breast cancer patients [35].  Hopefully, the results from this subgroup 
analysis can provide useful biomarker candidates to better identify drug targets to 
effectively treat certain types of breast cancer. 
4.1 The role of the IGF system in cancer growth and metastasis (SHC1) 
The possibility of the Src homology 2 domain-containing transforming protein C1 
(SHC1) being a breast cancer biomarker candidate is supported by numerous other 
studies.  SHC1 is a polymorphism that is located in important regulatory regions, such as 
in the promoter region of functionally active domains, which may affect the function of 
protein [37].  Insulin receptor substrates (IRS) and Src homology 2 domains—containing 
transforming protein 1’s (SHC1)—are key mediators of the insulin-like growth factor 
pathway [40, 41].  They act as docking proteins between the activated receptors and the 
further downstream signaling proteins.  IRS is a major substrate for the IGF receptor 
while the iRS2 and SHC1 proteins are tyrosine phosphorylated and can therefore interact 
and activate Scr homology 2 (SH2) domain containing proteins.  Both IRS and SHC1 can 
bind to growth factor receptor bound protein2 (GRB2) to activate the Ras/MAP kinase 
pathway that regulates cell proliferation.  Changes in the activity of the IRS and SHC1 
proteins may thus have an effect both on cell proliferation and apoptosis.  It has been 
shown that SHC1 is constitutively activated in a high number of human tumors, including 
breast tumors [42], and may explain the over expression of MAP kinase detected in many 
cancers [42, 43].  Since the fold change (1.22) is higher than the %CV (20%) of this 
protein in this study, there is further evidence to suggest that the SHC1 is expressed in 
different quantities in healthy and cancer patients.  Figure 4.1.1 shows the relative 
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expression levels of Src homology 2 domain-containing transforming protein C1 when 
comparing cancer sample group with control sample group. 
M
ea
n
 
Lo
g2
(In
te
n
s
ity
) +
/- 
St
dE
rr
1 2 .5
12 .6
12 .7
12 .8
12 .9
13 .0
13 .1
13 .2
13 .3
13 .4
0H 1C
group
 
 
Figure 4.1.1 Gene Name: SHC1, Protein Id=IPI00021326.4, SigChange=Yes, 
Annotation=SHC_ (Src_homology_2_domain_containing) _transforming_protein_1.  
Relative expression levels of SHC1 under different conditions.  The intensities which are 
given by the AUC from the XIC are transformed to the log base 2 scale, base 2 is popular 
because a two-fold change is transformed to a unit change on a log base 2 scale.  Error 
bars show standard errors based on the ANOVA model. 
4.2 Control of cell motility and tumor invasion by extracellular matrix interactions 
(FN1) 
Another reasonable breast cancer biomarker candidate in this study is the 
fibronectin1 protein (FN1).  Fibronectin (FN) is an example of an extracellular matrix 
(ECM) protein that promotes cell motility [46].  Cell movements largely depends on cell 
interactions with specific components of the ECM and is a fundamental feature of many 
normal and pathological processes, including developmental morphogenesis, 
  
 
 
        41 
inflammation, wound healing, and metastasis [45].  Fibulin-1 (FBIN1), a secreted 
calcium-binding glycoprotein assembled as insoluble polymers and presented in the 
blood as a soluble dimer, is found in association with ECM structures such as micro 
fibrils, basement membranes, elastic fibres, and fibrin.  The association of fibulin-1 with 
these ECM structures is probably based on its ability to bind ECM proteins such as 
fibronectin (FN), laminin, nidogen, and fibrinogen [47].  FN1 is a homologue of FN and 
contains a self-assembly domain, which induces FN1-FN1 polymerization [49].  FBLN1 
has been implicated in cellular transformation and tumor invasion.  It appears to be a 
tumor suppressor and may play a role in homeostasis and thrombosis owing to its ability 
to bind fibrinogen and incorporate it into clots [48].  Strong support for in vivo anti-tumor 
activity of polymeric FN1 exhibited anti-tumor activity in mice bearing various types of 
tumors [50].  Another report [51] showed that anastellin, a component of FN1 that is 
capable of inducing FN1 polymerization, displayed anti-angiogenic and anti-metastastic 
properties.  These findings provide a rational explanation for this study.  Figure 4.2.1 
shows the relative expression levels of fibronectin 1 protein when comparing cancer 
sample group with control sample group, the fold change is -1.23. 
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Figure 4.2.1 Relative expression levels of FN1 under different conditions  
Gene Name=FN1, variability Gauge Rank=17, Protein Id=IPI00411462.4, 
SigChange=Yes, Annotation=Fibronectin_1 
4.3 The role of acute-phase reactants in the modulation of the immune system: 
protein Orosomucoid1 (ORM1) 
Orosomucoid1 (ORM1) was also found to be differentially expressed in healthy 
and cancer patient in this study—higher levels in early stage breast cancer patients.  A 
Standard Error chart for this protein is shown in Figure 4.3.1.  Alpha1-acid glycoprotein, 
first described in 1950 by Schmid [38], belongs to a group of acute-phase proteins that 
may play a role in the modulation of the immune system in response to stress, along with 
many other functions [38].  In literature there are several studies concerning ORM1 
glycoform determination for the diagnosis of different types of cancer, such as colorectal 
[39] and ovarian cancer [39].  Also, serum level of ORM is increased in inflammatory 
and lymphoproliferative disorders and cancers, such as breast, lung and ovarian cancers 
[38], leading to the assumption that ORM might be produced by cancer cells themselves 
[39].  Therefore, ORM1 is an important candidate to study to increase the probability of 
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early detection in cancer patients.  The differential expression level of this protein (the 
fold change is 1.36) in different conditions is shown in Figure 4.3.1 in this study.  
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Figure 4.3.1 Relative expression levels of ORM1 under different conditions 
Gene Name=ORM1, variability Gauge Rank=37, Protein Id=IPI00022429.3, 
SigChange=Yes, Annotation=Alpha-1-acid_glycoprotein_1_precursor 
 
4.4 Proteins from subgrouping analysis: Haptoglobin (HP) and S100A8 as potential 
biomarkers for Luminal type B and Basal type breast cancer 
One of the major proteins, Haptoglobin, in subgroup P1 and P4 is expressed by 
the liver and secreted in plasma.  It combines with free plasma hemoglobin, preventing 
loss of iron through the kidneys and protecting the kidneys from damage by hemoglobin, 
while making the hemoglobin accessible to degradative enzymes.  Haptoglobin has 
recently been demonstrated as a serum marker for prostate cancer [44] and ovarian cancer 
[52].  In this study, haptoglobin is the strongest biomarker candidate increased in 
Luminal type B (2.1-fold) but less so in Basal (1.4-fold).  This protein has previously 
been shown to be up-regulated in breast cancer and is associated with metastasis 
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recurrence [53].  It is up-regulated by Nuclear factor-KB (NF-KB is a ubiquitous 
transcription factor that controls the expression of genes involved in immune responses, 
apoptosis, and cell cycle), but this induction is repressed by estrogen receptor.  The loss 
of estrogen receptor and NF-KB crosstalk may lead to elevated expression [53]. 
The next candidate S100 A8 is a calcium binding protein.  It is made in larger amounts in 
inflammatory diseases such as rheumatoid arthritis, and in some types of cancer [54].  In 
this study, it increased in Luminal B (1.5-fold) but not basal (1-fold).  It induces NF-KB 
activity [55].  Previous studies have shown its elevation in basal-type breast cancer [54].  
In our studies it is elevated in Luminal type B.  This protein has been shown in a few 
literatures to be related with other cancers, for example bladder cancer [56].  The 
differential expression levels of haptoglobin and S100 A8 in the subgroups are shown 
Figure 4.4.1 and Figure 4.4.2 below. 
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Figure 4.4.1 Relative expression levels of haptoglobin under different conditions  
Rank=1, Protein Id=IPI00641737.1, SigChange=Yes, Annotation=Haptoglobin 
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Figure 4.4.2 Relative expression levels of S100 A8 under different conditions 
Rank=28, Protein Id=IPI00007047.1, SigChange=Yes, Annotation=Protein_S100-A8 
4.5 Summary 
 From this study, Src homology 2 domain-containing transforming protein C1 
(SHC1), fibronectin 1 protein (FN1) and orosomucoid 1 protein (ORM1) were selected as 
biomarker candidates in early stage breast cancer when comparing 40 breast cancer 
patients and healthy control samples.  Haptoglobin protein (HP) and S100A8 protein 
  
 
 
        46 
were selected as biomarker candidates for Luminal type B and Basal type breast cancer 
when the breast cancer patients were divided into four sub-groups and compared with 
healthy control samples.  Sub-grouping can lead to a more targeted approach 
personalized medicine in the development of breast cancer treatments, tailoring 
treatments to a specific type of breast cancer.  The fold changes after sub-grouping were 
significantly higher than normal grouping.  The data from sub-grouping was consistent 
with recent literature in which pharmaceutical companies used biomarkers from sub-
grouping to develop personalized medicine more efficiently [36].  As a follow up, a study 
to validate these selected biomarker candidates with and without sub-grouping is 
necessary. 
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5. Conclusion 
The results from this study showed that LC/MS label-free protein quantification 
technology with statistical analysis allows for detection of, not only more low-abundance 
proteins, but also proteins with small changes in expression.  This method along with 
bioinformatics analysis provides an excellent opportunity to identify potential biomarkers 
for early stage breast cancer, however, any discoveries made by proteomic approaches 
should be validated using different methods.  Once these potential biomarkers are 
confirmed and validated, they can then serve as targets for early diagnostics and 
therapeutics development. 
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Appendix 1:  The information of all 385 proteins (priority 1-4) with significant changes 
(q value less than 5%) using LC/MS-based label free protein quantification method 
 
Protein_ID Gene 
symbol 
FC  qValue  Annotation Biological Process 
IPI00022431.1 AHSG -1.20 0.001 Alpha-2-HS-
glycoprotein_precursor 
P: regulation of 
inflammatory response    
 P: positive regulation of 
phagocytosis    P: 
pinocytosis    P: negative 
regulation of insulin 
receptor sig...    P:negative 
regulation of bone 
mineralization    P:acute-
phase response     
225768 SAA1 1.21 0.001 1313184B_alpha1_antitr
ypsin 
P:electron transport     
IPI00164623.4 C3 1.12 0.001 187_kDa_protein  
IPI00783987.1 C3 1.12 0.001 Complement_C3_precur
sor_(Fragment) 
P: immune response    
 P: G-protein coupled 
receptor protein signalin...     
671882 APOA2 -1.28 0.001 apolipoprotein_[Homo_s
apiens] 
P: response to glucose 
stimulus    P: regulation of 
cytokine production     
P: positive regulation of 
interleukin-8 biosyn...    
 P: neutrophil activation    
 P: negative regulation of 
lipoprotein metaboli...    
P:negative regulation of 
lipid catabolic process    
P:lipid transport    P:glucose 
metabolic process     
IPI00021854.1 APOA2 -1.30 0.002 Apolipoprotein_A-
II_precursor 
 
IPI00305457.5 SERPINA1 1.18 0.002 PRO2275  
IPI00431656.4 SERPINA3 1.15 0.002 Isoform_2_of_Alpha-1-
antichymotrypsin_precur
s 
P:regulation of lipid 
metabolic process    
P:inflammatory response     
223433 DAP13 1.17 0.002 0805684B_inhibitor,alp
ha1_protease 
 
225769  1.13 0.002 1313184C_chymotrypsi
n_inhibitor 
 
IPI00550991.2 SERPINA3 1.13 0.003 Isoform_1_of_Alpha-1-
antichymotrypsin_precur
sor 
 
IPI00294004.1 PROS1 1.09 0.004 Vitamin_K-
dependent_protein_S_pr
ecursor 
P:blood coagulation     
IPI00553177.1 SERPINA1 1.16 0.004 Alpha-1-
antitrypsin_precursor 
 
40737516 C4B 1.21 0.004 C4A6_[Homo_sapiens]  
IPI00032258.4 C4A 1.18 0.004 Complement_C4-
A_precursor 
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177836 SERP1NA1 1.15 0.004 alpha-1-
antitrypsin_precursor 
 
IPI00411462.4 FN1 -1.23 0.004 fibronectin_1_isoform_7
_preproprotein 
 
IPI00418163.3 C4B 1.17 0.004 complement_component
_4B_preproprotein 
 
40737408 C4B 1.17 0.004 C4B5_[Homo_sapiens] P:complement activation     
IPI00003351.2 ECM1 -1.09 0.006 Extracellular_matrix_pr
otein_1_precursor 
P: positive regulation of I-
kappaB kinase/NF-k...     
229453  -1.09 0.006 731316A_plasminogen_
1-69 
 
IPI00028413.7 ITIH3 1.11 0.007 Inter-alpha-
trypsin_inhibitor_heavy
_chain_H3_precursor 
 
4758236 ECM1 -1.08 0.008 extracellular_matrix_pro
tein_1_isoform_1_precu
rsor_[Homo_sapiens] 
 
3024064 ITIH3 1.11 0.009 ITIH3_HUMAN_Inter-
alpha-
trypsin_inhibitor_heavy
_chain_H3_precursor_(I
TI_heavy_chain_H3)_(I
nter-alpha-
inhibitor_heavy_chain_3
)_(Serum-
derived_hyaluronan-
associated_protein)_(SH
AP) 
 
30722344  -1.19 0.009 hypothetical_protein_[H
omo_sapiens] 
P: transmembrane receptor 
protein tyrosine kin...    
P:response to wounding    
P:cell migration    P:cell 
adhesion     
IPI00022418.1 FN1 -1.19 0.009 Isoform_1_of_Fibronect
in_precursor 
 
IPI00022395.1 C9 1.11 0.009 Complement_componen
t_C9_precursor 
P:hemolysis by symbiont of 
host red blood cells     
IPI00296165.5 C1R 1.09 0.011 Complement_C1r_subco
mponent_precursor 
P:immune response     
34365361 DKFZp686O
12165 
-1.18 0.012 hypothetical_protein_[H
omo_sapiens] 
P:acute-phase response     
223962 C4d 1.15 0.013 1006226B_complement
_C4d_variant 
P: carbon utilization by 
fixation of carbon di...     
IPI00019580.1 PLG -1.06 0.014 Plasminogen_precursor P: negative regulation of 
cell proliferation    
P:negative regulation of 
blood vessel endothe...    
P:negative regulation of 
angiogenesis    P:induction 
of apoptosis    P:blood 
coagulation     
IPI00009920.2 C6 1.07 0.014 Complement_componen
t_C6_precursor 
 
  
 
 
        50 
13787109  1.13 0.014 A_Chain_A,_A_2.1_An
gstrom_Structure_Of_A
n_Uncleaved_Alpha-1-
_Antitrypsin_Shows_Va
riability_Of_The_Reacti
ve_Center_And_Other_
Loops 
 
IPI00032291.1 C5 1.11 0.014 Complement_C5_precur
sor 
P: inflammatory response    
P: G-protein coupled 
receptor protein signalin...    
P:chemotaxis    P:activation 
of MAPK activity     
899271 C7 1.11 0.015 complement_C7_[Homo
_sapiens] 
P:complement activation     
IPI00017696.1 C1S 1.07 0.015 Complement_C1s_subco
mponent_precursor 
 
IPI00022429.3 ORM1 1.36 0.015 Alpha-1-
acid_glycoprotein_1_pre
cursor 
P:acute-phase response     
38488662 C6 1.07 0.015 complement_component
_6_[Homo_sapiens] 
P:complement activation     
229386  1.43 0.017 720005A_protein,alpha1
_acid_glyco 
 
IPI00019943.1 AFM -1.11 0.017 Afamin_precursor  
IPI00303152.4 COL22A1 -1.09 0.017 collagen,_type_XXII,_al
pha_1 
P:cell adhesion     
21707947 ECM1 1.15 0.017 Leucine-rich_alpha-2-
glycoprotein_1_[Homo_
sapiens] 
 
IPI00001611.1 IGF2 1.08 0.020 Isoform_1_of_Insulin-
like_growth_factor_II_p
recursor 
P:skeletal development    
P:insulin receptor signaling 
pathway    P:genetic 
imprinting     
39725934 SERPINF1 1.08 0.023 serine_(or_cysteine)_pro
teinase_inhibitor,_clade
_F_(alpha-
2_antiplasmin,_pigment
_epithelium_derived_fac
tor),_member_1_[Homo
_sapiens] 
P:positive regulation of 
neurogenesis    P:negative 
regulation of angiogenesis    
P:cell proliferation     
179716 C7 1.11 0.023 complement_protein_C7
_precursor 
 
IPI00009793.2 C1RL 1.05 0.023 Complement_componen
t_1,_r_subcomponent-
like_variant_(Fragment) 
P:proteolysis     
IPI00296608.6 C7 1.11 0.025 Complement_componen
t_C7_precursor 
 
IPI00006114.4 SERPINF1 1.08 0.025 Pigment_epithelium-
derived_factor_precurso
r 
 
IPI00022426.1 AMBP 1.08 0.026 AMBP_protein_precurs
or 
P:negative regulation of 
JNK cascade    P:negative 
regulation of immune 
response    P:heme catabolic 
process    P:female 
pregnancy    P:cell adhesion    
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IPI00027462.1 S100A9 1.10 0.026 Protein_S100-A9 P:inflammatory response    
P:cell-cell signaling     
IPI00026199.1 GPX3 -1.08 0.026 Glutathione_peroxidase_
3_precursor 
P:response to lipid 
hydroperoxide    P:protein 
homotetramerization    
P:hydrogen peroxide 
catabolic process     
13937839 SAA1 1.14 0.029 SAA1_protein_[Homo_s
apiens] 
P: positive regulation of 
interleukin-1 secretion    P: 
positive regulation of cell 
adhesion    P: platelet 
activation    P:neutrophil 
chemotaxis    P:negative 
regulation of inflammatory 
response    P:macrophage 
chemotaxis    P:lymphocyte 
chemotaxis    P:elevation of 
cytosolic calcium ion 
concentr...    P:acute-phase 
response     
10436374  1.05 0.037 unnamed_protein_produ
ct_[Homo_sapiens] 
P:proteolysis     
178818 APOB -1.08 0.038 apolipoprotein_B-100 P:signal transduction    
P:lipid transport    P:blood 
circulation     
40316910 SAA2 1.16 0.040 serum_amyloid_A1_isof
orm_2_[Homo_sapiens] 
 
15029894 SERPING1 1.08 0.040 Serpin_peptidase_inhibit
or,_clade_G_(C1_inhibit
or),_member_1,_(angioe
dema,_hereditary)_[Ho
mo_sapiens] 
P:blood circulation     
IPI00022417.4 LRG1 1.16 0.040 Leucine-rich_alpha-2-
glycoprotein_precursor 
 
229479  -1.19 0.046 740525A_lipoprotein_G
ln_I 
 
IPI00002286.5 ANKRD11 1.23 0.000 Ankyrin_repeat_domain
-containing_protein_11 
 
IPI00217617.4 MPP7 -1.20 0.000 palmitoylated_membran
e_protein_7 
 
IPI00218852.2 VIL1 -1.24 0.000 Villin-1 P:protein complex assembly    
P:actin filament severing     
IPI00748360.1 KIAA1797 -1.30 0.000 Novel_gene  
IPI00295640.3 ABCA6 -1.30 0.000 Isoform_1_of_ATP-
binding_cassette_sub-
family_A_member_6 
 
IPI00011245.1 USP29 1.20 0.000 Ubiquitin_carboxyl-
terminal_hydrolase_29 
P:protein modification 
process     
IPI00445774.1 GPR113 -1.28 0.000 CDNA_FLJ43404_fis,_
clone_OCBBF2017516 
 
IPI00165955.1 MAPK15 1.16 0.001 Isoform_1_of_Mitogen-
activated_protein_kinase
_15 
P:protein amino acid 
autophosphorylation     
IPI00375286.3 KIAA0802 -1.19 0.001 KIAA0802_protein  
IPI00333913.7 NAG -1.45 0.001 neuroblastoma-
amplified_protein 
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IPI00026108.1 PLA2G4A 1.17 0.001 Cytosolic_phospholipase
_A2 
P:platelet activating factor 
biosynthetic process    
P:icosanoid metabolic 
process     
IPI00440493.2 ATP5A1 1.18 0.001 ATP_synthase_subunit_
alpha,_mitochondrial_pr
ecursor 
 
IPI00003843.1 TJP2 1.13 0.002 Isoform_A1_of_Tight_j
unction_protein_ZO-2 
 
IPI00465430.5  -1.26 0.002 70_kDa_protein  
IPI00219561.1 NLRP14 1.18 0.002 NACHT,_LRR_and_PY
D-
containing_protein_14 
P:spermatogenesis     
IPI00001364.2 C21orf66 1.18 0.002 Isoform_A_of_GC-
rich_sequence_DNA-
binding_factor_homolog 
P:regulation of transcription, 
DNA-dependent     
IPI00025418.1 COL7A1 -1.28 0.002 Collagen_alpha-
1(VII)_chain_precursor 
P:epidermis development     
IPI00152774.1 ARL6IP4 1.16 0.003 FLJ00169_protein_(Frag
ment) 
 
IPI00256429.3 MYO7B 1.19 0.004 PREDICTED:_myosin_
VIIB 
 
IPI00009891.1 TAF1 -1.20 0.004 Isoform_1_of_Transcrip
tion_initiation_factor_T
FIID_subunit_1 
P:protein amino acid 
autophosphorylation    P:G1 
phase of mitotic cell cycle     
IPI00045550.3 PPP1R9B 1.22 0.004 Neurabin-2  
32967319  1.14 0.005 ephrin_receptor_EphA5
_isoform_b_[Homo_sapi
ens] 
 
8885790 FLNC -1.24 0.005 AF146692_1_filamin_2
_[Homo_sapiens] 
 
IPI00029449.6 VANGL2 1.14 0.005 Vang-like_protein_2 P:sensory cilium biogenesis    
P:neural tube closure    
P:heart looping    
P:establishment of planar 
polarity    P:apical protein 
localization     
IPI00413728.3 SPTAN1 1.14 0.005 Isoform_1_of_Spectrin_
alpha_chain,_brain 
 
IPI00100460.2 DARS2 -1.34 0.005 Aspartyl-
tRNA_synthetase,_mito
chondrial_precursor 
 
IPI00304267.3 NXN 1.23 0.007 nucleoredoxin P:electron transport     
IPI00412404.1 SUPV3L1 -1.32 0.007 Putative_ATP-
dependent_mitochondria
l_RNA_helicase 
 
IPI00303944.6 NSUN4 1.08 0.007 NOL1/NOP2/Sun_doma
in_family_4_protein 
 
IPI00003590.2 QSOX1 1.13 0.009 Isoform_1_of_Sulfhydry
l_oxidase_1_precursor 
P:protein thiol-disulfide 
exchange     
IPI00014215.5 HYDIN 1.16 0.009 HYDIN_protein  
IPI00169256.1 HBE269 -1.12 0.011 HBE269  
IPI00303530.4 MTHFSD 1.09 0.011 CDNA_FLJ13893_fis,_
clone_THYRO1001661 
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IPI00022470.2 ZN516 1.17 0.011 PREDICTED:_similar_t
o_Zinc_finger_protein_5
16 
 
IPI00030059.1 GNG10 -1.15 0.011 Guanine_nucleotide-
binding_protein_G(I)/G(
S)/G(O)_gamma-
10_subunit_precursor 
P:signal transduction     
IPI00293887.4 STARD8 -1.12 0.011 Hypothetical_protein_D
KFZp686H1668 
P:signal transduction     
IPI00550021.3 RPL3 1.14 0.011 60S_ribosomal_protein_
L3 
P:translation     
IPI00413895.2 GOLGA2 -1.21 0.011 Golgi_autoantigen,_golg
in_subfamily_A_membe
r_2 
 
IPI00102936.3 SRP68 -1.21 0.011 Isoform_2_of_Signal_re
cognition_particle_68_k
Da_protein 
 
IPI00003515.1 TRIP11 1.21 0.011 Thyroid_receptor-
interacting_protein_11 
P:transcription from RNA 
polymerase II promoter     
IPI00002564.3 XRCC1 1.22 0.011 DNA-
repair_protein_XRCC1 
 
IPI00029661.2 EVI5 1.22 0.011 ecotropic_viral_integrati
on_site_5 
P:multicellular organismal 
development    P:cell 
proliferation     
IPI00465166.1 ATP8A2 1.11 0.012 CDNA_FLJ45330_fis,_
clone_BRHIP3007195,_
highly_similar_to_Poten
tial_phospholipid-
transporting_ATPase_IB 
P:cation transport     
IPI00008456.1 HSF4 1.11 0.013 Isoform_HSF4B_of_He
at_shock_factor_protein
_4 
P:regulation of transcription, 
DNA-dependent     
IPI00332837.1 PLEKHA7 -1.21 0.014 PLEKHA7_protein_(Fra
gment) 
 
IPI00166085.1 LGI2 -1.26 0.016 Leucine-
rich_repeat_LGI_family
_member_2_precursor 
 
IPI00096899.6 CDT1 -1.16 0.016 DNA_replication_factor
_Cdt1 
P:DNA replication 
checkpoint     
IPI00165984.4 WDR35 1.15 0.016 Isoform_1_of_WD_repe
at_protein_35 
 
IPI00175649.3 LRRK2 1.08 0.016 Leucine-
rich_repeat_serine/threo
nine-protein_kinase_2 
 
IPI00060148.3 CCDC127 -1.10 0.016 Coiled-
coil_domain_containing
_127 
 
IPI00744612.1 PRDM5 1.22 0.016 Conserved_hypothetical
_protein 
 
IPI00018903.1 VAX2 1.36 0.016 Ventral_anterior_homeo
box_2 
P:visual perception    
P:ectoderm development     
IPI00556155.1 IGFBP3 1.14 0.016 insulin-
like_growth_factor_bind
ing_protein_3_isoform_
a_precursor 
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IPI00156532.1 ULK4 1.19 0.017 Hypothetical_protein_F
LJ20574 
 
IPI00244116.1 C1ORF67 -1.12 0.019 Novel_protein  
IPI00155475.5 KCTD19 -1.18 0.021 KCTD19_protein  
IPI00293925.2 FCN3 1.13 0.021 Isoform_1_of_Ficolin-
3_precursor 
 
IPI00013492.1 TCF4 -1.18 0.021 Isoform_SEF2-
1B_of_Transcription_fa
ctor_4 
P: positive regulation of 
transcription, DNA-d...     
IPI00218803.2 FBLN1 -1.06 0.024 Isoform_B_of_Fibulin-
1_precursor 
 
IPI00298935.4 JMJD1B -1.18 0.025 Isoform_1_of_JmjC_do
main-
containing_histone_dem
ethylation_protein_2B 
 
8176715 GIPR 1.08 0.026 glucose-
dependent_insulinotropi
c_polypeptide_receptor;
_GIP_receptor_[Homo_
sapiens] 
P:response to nutrient    
P:generation of precursor 
metabolites and energy    
P:adenylate cyclase 
activation     
IPI00787774.1 LOC730756 -1.22 0.026 PREDICTED:_similar_t
o_collagen,_type_I,_alp
ha_1 
 
IPI00736556.3 KIAA1486 -1.12 0.026 PREDICTED:_similar_t
o_myosin_heavy_chain_
Myr_8_isoform_1 
 
IPI00005794.1 PGCP -1.12 0.026 Blood_plasma_glutamat
e_carboxypeptidase_pre
cursor 
 
22760630 WDR31 -1.17 0.027 unnamed_protein_produ
ct_[Homo_sapiens] 
 
IPI00069084.1 TRRAP 1.10 0.028 Isoform_1_of_Transfor
mation/transcription_do
main-associated_protein 
P:signal transduction    
P:histone acetylation     
IPI00385791.1 MRPS26 1.17 0.031 Serologically_defined_b
reast_cancer_antigen_N
Y-BR-87_(Fragment) 
 
30268327 TXLNA -1.23 0.032 hypothetical_protein_[H
omo_sapiens] 
P:cell proliferation     
IPI00026940.2 NUP50 -1.16 0.032 Nucleoporin_50_kDa  
IPI00549941.2 LOC220115 1.23 0.033 TPTEps1_protein_(Frag
ment) 
 
IPI00761046.1  1.10 0.036 Conserved_hypothetical
_protein 
 
IPI00008556.1 F11 1.06 0.036 Isoform_1_of_Coagulati
on_factor_XI_precursor 
P:blood coagulation     
IPI00215631.1 VCAN -1.25 0.036 Isoform_Vint_of_Versic
an_core_protein_precurs
or 
P:multicellular organismal 
development    P:cell 
recognition    P:cell 
adhesion     
IPI00339217.2 OVCH1 1.17 0.041 ovochymase_1  
IPI00028493.3 TSC2 1.12 0.042 Isoform_1_of_Tuberin P:regulation of progression 
through cell cycle    
P:endocytosis     
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IPI00182757.9 KIAA1967 1.09 0.047 Isoform_2_of_Protein_
KIAA1967 
 
IPI00177967.6 MPHOSPH9 1.16 0.001 M-
phase_phosphoprotein_9 
 
IPI00179164.2 KIAA1244 -1.19 0.002 hypothetical_protein_L
OC57221 
 
IPI00299503.1 GPLD1 -1.10 0.004 Phosphatidylinositol-
glycan-
specific_phospholipase_
D_1_precursor 
 
IPI00023824.1 FBLN2 1.10 0.006 Fibulin-2_precursor  
IPI00397927.1 FLJ46347 1.14 0.009 CDNA_FLJ46347_fis,_
clone_TESTI4047437 
 
IPI00398808.5 WNK2 -1.08 0.023 Isoform_1_of_Serine/thr
eonine-
protein_kinase_WNK2 
P:protein kinase cascade    
P:protein amino acid 
phosphorylation     
IPI00103516.1 CASKIN2 -1.08 0.023 Caskin-2  
IPI00152462.1 DNAH3 1.05 0.027 Axonemal_heavy_chain
_dynein_type_3 
 
IPI00299635.3 BIRC6 -1.09 0.027 Baculoviral_IAP_repeat-
containing_protein_6 
P:anti-apoptosis     
IPI00218539.3 COL11A1 -1.09 0.028 Isoform_B_of_Collagen
_alpha-
1(XI)_chain_precursor 
P: visual perception    P: 
extracellular matrix 
organization and bioge...    
P:cartilage condensation     
IPI00026320.1 UBR5 1.08 0.030 Ubiquitin-
protein_ligase_EDD1 
P:ubiquitin-dependent 
protein catabolic process    
P:response to DNA damage 
stimulus    P:progesterone 
receptor signaling pathway    
P:cell proliferation     
IPI00411743.5 CCDC15 1.09 0.033 CCDC15_protein_(Frag
ment) 
 
IPI00102752.2 RBM15 1.09 0.038 Isoform_1_of_Putative_
RNA-
binding_protein_15 
 
IPI00289275.2 CILP -1.31 0.001 Cartilage_intermediate_l
ayer_protein_1_precurso
r 
P: nucleobase, nucleoside, 
nucleotide and nucl...     
IPI00031666.4 RP3-
402G11.5 
-1.29 0.001 Selenoprotein_O  
IPI00026321.3 GFM1 -1.37 0.001 CDNA_FLJ12662_fis,_
clone_NT2RM4002205,
_moderately_similar_to_
ELONGATION_FACT
OR_G,_MITOCHOND
RIAL 
 
IPI00749092.1  -1.30 0.001 Similar_to_Phosphoinos
itide_3-phosphatase 
 
IPI00455122.1  -1.30 0.001 Novel_protein  
IPI00219005.2 FKBP4 -1.30 0.001 FK506-
binding_protein_4 
P:protein folding     
1097307  -1.26 0.001 2113367A_HIC-1_gene P:metabolic process     
IPI00376259.1 SRGAP1 1.17 0.001 Isoform_1_of_SLIT-
ROBO_Rho_GTPase-
activating_protein_1 
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IPI00250364.1 TAS2R60 -1.50 0.001 Taste_receptor_type_2_
member_60 
P:sensory perception of 
bitter taste     
IPI00011875.1 IK -1.49 0.001 Protein_Red P:immune response    P:cell-
cell signaling     
3024656  1.18 0.001 SOX12_HUMAN_SOX
-12_protein_(SOX-
22_protein) 
P: regulation of transcription 
from RNA polyme...     
IPI00477676.2 LOXHD1 1.18 0.001 LOXHD1_protein  
IPI00102677.1 TESK2 1.17 0.001 Isoform_1_of_Dual_spe
cificity_testis-
specific_protein_kinase_
2 
P:spermatogenesis    
P:protein amino acid 
phosphorylation    P:focal 
adhesion formation    P:actin 
cytoskeleton organization 
and biogenesis     
IPI00455063.4 MIXED 1.22 0.001 PREDICTED:_similar_t
o_leiomodin_2 
 
IPI00746871.1  1.18 0.001 Similar_to_Alu_subfami
ly_SQ_sequence_conta
mination_warning_entry 
 
IPI00029501.1 SEBOX 1.20 0.001 SEBOX  
IPI00651656.1 GRASP 1.20 0.001 Isoform_2_of_General_r
eceptor_for_phosphoino
sitides_1-
associated_scaffold_prot
ein 
 
IPI00166215.4 INTS1 -1.16 0.001 Integrator_complex_sub
unit_1 
 
IPI00167515.1 ZADH1 1.18 0.001 Isoform_1_of_Zinc-
binding_alcohol_dehydr
ogenase_domain-
containing_protein_1 
 
IPI00291186.5 SLC7A13 1.18 0.001 solute_carrier_family_7,
_(cationic_amino_acid_t
ransporter,_y+_system)_
member_13 
P:amino acid transport     
IPI00004939.1  1.20 0.001 Neuronal_thread_protein
_AD7c-NTP 
P:central nervous system 
development    P:apoptosis     
IPI00216662.5 TMPRSS6 1.20 0.001 Isoform_3_of_Transme
mbrane_protease,_serine
_6 
P: proteolysis    P: 
intracellular signaling 
cascade    P: fibrinolysis    
P:extracellular matrix 
organization and bioge...    
P:angiogenesis     
IPI00295368.1 GCNT1 1.18 0.001 Beta-1,3-galactosyl-O-
glycosyl-
glycoprotein_beta-1,6-
N-
_acetylglucosaminyltran
sferase 
P:protein amino acid O-
linked glycosylation     
IPI00002459.4 ANXA6 1.18 0.001 annexin_VI_isoform_2  
IPI00102291.1 FAM126A 1.18 0.001 Protein_FAM126A  
IPI00783147.1 LOC401387 1.18 0.001 84_kDa_protein  
IPI00011547.2 NAIP -1.30 0.001 Baculoviral_IAP_repeat-
containing_protein_1 
P:nervous system 
development    P:anti-
apoptosis     
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IPI00012842.1 SLC26A4 -1.15 0.001 Pendrin P:sulfate transport    
P:sensory perception of 
sound     
IPI00787902.1  -1.14 0.001 PREDICTED:_similar_t
o_Serine_protease_inhib
itor_Kazal-
type_7_precursor 
 
IPI00293593.2 TCTE1 1.18 0.001 OTTHUMP0000001652
4 
 
IPI00021388.1 MED13 1.18 0.001 Thyroid_hormone_recep
tor-
associated_protein_com
plex_240_kDa_compone
nt 
P: transcription initiation 
from RNA polymeras...    P: 
positive regulation of 
transcription from R...    
P:androgen receptor 
signaling pathway     
IPI00409601.1 KIAA1219 -1.34 0.001 Isoform_1_of_Protein_
KIAA1219 
 
IPI00394796.4 TDRD1 1.18 0.001 tudor_domain_containin
g_1 
 
IPI00169306.1 PFN4 -1.14 0.001 Profilin-4  
IPI00028064.1 CTSG 1.15 0.001 Cathepsin_G_precursor P:proteolysis    P:immune 
response     
IPI00399257.2 DCHS2 1.16 0.001 CDNA_FLJ45804_fis,_
clone_NT2RI3005923,_
weakly_similar_to_Cadh
erin-
_related_tumor_suppress
or 
P:homophilic cell adhesion     
IPI00023258.5 TAF4B 1.17 0.001 PREDICTED:_similar_t
o_Transcription_initiatio
n_factor_TFIID_105_k
Da_subunit 
 
IPI00217972.4 COL27A1 -1.18 0.001 Collagen_XXVII_proalp
ha_1_chain_precursor 
 
IPI00410330.3 GATAD2A -1.26 0.002 Isoform_1_of_Transcrip
tional_repressor_p66_al
pha 
P: negative regulation of 
transcription, DNA-d...    
P:DNA methylation     
IPI00029928.2 ELN 1.17 0.002 Isoform_2_of_Elastin_p
recursor 
P:respiratory gaseous 
exchange    P:organ 
morphogenesis    P:blood 
circulation    P:cell 
proliferation     
33187736  1.19 0.002 PCPD_protein_[Homo_s
apiens] 
 
IPI00145121.5 PIGB -1.15 0.002 GPI_mannosyltransferas
e_3 
P:GPI anchor biosynthetic 
process     
IPI00005822.1 CDC23 -1.25 0.002 Isoform_1_of_Cell_divi
sion_cycle_protein_23_
homolog 
P:cell division     
IPI00006602.3 NDEL1 -1.17 0.002 nudE_nuclear_distributi
on_gene_E_homolog_li
ke_1_(A._nidulans)_isof
orm_A 
 
IPI00400922.4 PDCD11 1.16 0.003 RRP5_protein_homolog  
IPI00387132.5 hCG_200735
4 
-1.27 0.003 CDNA_FLJ32661_fis,_
clone_TESTI1000055,_
weakly_similar_to_HO
MEOBOX_PROTEIN_
SIX1 
P:regulation of transcription, 
DNA-dependent     
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IPI00414320.1 ANXA11 1.17 0.003 Annexin_A11 P:immune response     
IPI00218946.2 HCN2 -1.24 0.003 Potassium/sodium_hype
rpolarization-
activated_cyclic_nucleot
ide-gated_channel_2 
P:muscle contraction    
P:cell-cell signaling    
P:cation transport     
IPI00304409.3 CARHSP1 1.20 0.003 Calcium-
regulated_heat_stable_pr
otein_1 
P:intracellular signaling 
cascade     
IPI00646062.3 KLHDC8A 1.17 0.003 Kelch_domain-
containing_protein_8A 
 
IPI00030739.1 APOM -1.14 0.003 Apolipoprotein_M P:membrane lipid metabolic 
process    P:generation of 
precursor metabolites and 
energy     
IPI00152424.1 SLC2A12 1.16 0.004 solute_carrier_family_2
_(facilitated_glucose_tra
nsporter),_member_12 
 
IPI00418802.1 LOC400968 -1.14 0.004 CDNA_FLJ45884_fis,_
clone_OCBBF3021166 
 
IPI00030939.3 GNAS -1.16 0.005 Alpha_subunit_of_GsG
TP_binding_protein 
P: G-protein coupled 
receptor protein signalin...     
IPI00383161.1  1.28 0.005 Serine/threonine_protein
_kinase_kkialre-like_1 
 
IPI00164387.1 KCNMA1 1.16 0.005 Isoform_5_of_Calcium-
activated_potassium_cha
nnel_subunit_alpha_1 
P:synaptic transmission    
P:potassium ion transport     
IPI00744443.1  1.53 0.005 Similar_to_calcium_cha
nnel,_voltage-
dependent,_alpha_2/delt
a_3_subunit 
 
IPI00008868.3 MAP1B -1.23 0.005 Microtubule-
associated_protein_1B 
 
IPI00395834.3  1.14 0.005 116_kDa_protein  
IPI00479962.3 MYO5B -1.09 0.006 Myosin-5B  
IPI00640963.1 NAP1L6 -1.21 0.006 12_kDa_protein  
IPI00030255.1 PLOD3 1.28 0.006 Procollagen-lysine,2-
oxoglutarate_5-
dioxygenase_3_precurso
r 
P:protein modification 
process     
IPI00152422.1 FLJ42875 -1.16 0.006 Hypothetical_protein_D
KFZp761G0122 
 
IPI00167908.3 IQUB 1.10 0.006 FLJ35834_protein  
IPI00386442.5 KIFAP3 1.14 0.006 Kinesin-
associated_protein_3 
P:signal transduction    
P:protein complex assembly    
P:microtubule-based process    
IPI00329444.3 ACSM2B -1.15 0.008 Hypothetical_protein_H
YST1046 
 
IPI00015963.2 TRPA1 -1.24 0.008 Transient_receptor_pote
ntial_cation_channel_su
bfamily_A_member_1 
P:ion transport     
IPI00065931.2 AKAP13 1.10 0.008 A-
kinase_anchor_protein_
13_isoform_1 
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IPI00185919.3 LARP1 -1.23 0.009 Isoform_1_of_La-
related_protein_1 
 
IPI00012451.2 GNB4 1.09 0.009 Guanine_nucleotide-
binding_protein_subunit
_beta_4 
 
IPI00166009.2 FBXL11 -1.22 0.009 Isoform_1_of_JmjC_do
main-
containing_histone_dem
ethylation_protein_1A 
 
IPI00442880.1 Q6ZP64 1.15 0.009 Hypothetical_protein_F
LJ26451 
 
IPI00306604.5 ITGA5 -1.14 0.009 Integrin_alpha-
5_precursor 
P:cell adhesion     
IPI00740057.2 ANKRD31 -1.19 0.009 PREDICTED:_similar_t
o_Ankyrin_repeat_doma
in-
containing_protein_11 
 
IPI00216061.3 PRR5 -1.19 0.009 proline_rich_5_(renal)_i
soform_2 
 
IPI00011919.1 FADD -1.15 0.010 FADD_protein P: positive regulation of I-
kappaB kinase/NF-k...    P: 
induction of apoptosis via 
death domain rec...     
8923808 EPHA5 -1.21 0.010 erythropoietin_4_immed
iate_early_response_[Ho
mo_sapiens] 
 
IPI00787100.1 LOC728328 -1.14 0.010 PREDICTED:_similar_t
o_procollagen,_type_I,_
alpha_2 
 
18086504 CYP4B1 1.15 0.011 cytochrome_P450_[Ho
mo_sapiens] 
 
IPI00017672.4  1.18 0.011 Hypothetical_protein_F
LJ25678 
 
IPI00166002.3 PSD3 -1.14 0.011 PSD3_protein  
1684923  -1.41 0.011 This_CDS_feature_is_in
cluded_to_show_the_tra
nslation_of_the_corresp
onding_V_region,_parti
al_cds_Presently_transla
tion_qualifiers_on_V_re
gion_features_are_illega
l 
 
13543559 NDUFA12 
(DAP13) 
1.14 0.011 NADH_dehydrogenase_
(ubiquinone)_1_alpha_s
ubcomplex,_12_[Homo_
sapiens] 
P:response to oxidative 
stress    P:respiratory 
gaseous exchange     
IPI00032358.3 POM121 -1.48 0.011 Nuclear_envelope_pore_
membrane_protein_PO
M_121 
 
IPI00470901.3 PPP2R2A -1.36 0.011 CDNA_FLJ41613_fis,_
clone_CTONG3002412,
_moderately_similar_to_
Human_DOCK180_prot
ein_mRNA. 
 
IPI00397393.2 KIAA1549 -1.38 0.011 PREDICTED:_similar_t
o_K06A9.1b_isoform_2 
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34535254 DNAH17 1.09 0.013 unnamed_protein_produ
ct_[Homo_sapiens] 
 
IPI00413385.1 ITIH5L -1.31 0.013 ITI-like_protein  
IPI00410324.1 LSM12 -1.31 0.013 LSM12_homolog  
IPI00019312.2 G7C 1.14 0.013 Protein_G7c_precursor  
IPI00302660.2 VPS37A 1.17 0.013 Vacuolar_protein_sortin
g_37_homolog_A 
 
IPI00142538.3 SETX 1.17 0.013 Isoform_1_of_Probable_
helicase_senataxin 
P:RNA processing    
P:double-strand break repair    
IPI00030045.2 PROK2 1.17 0.013 Isoform_1_of_Prokineti
cin-2_precursor 
P: spermatogenesis    P: 
sensory perception of pain    
P: positive regulation of 
smooth muscle contra...    P: 
inflammatory response    P: 
G-protein coupled receptor 
protein signalin...    P: 
elevation of cytosolic 
calcium ion concentr...    
P:chemotaxis    P:cell 
proliferation    P:anti-
apoptosis    P:angiogenesis    
P:activation of MAPK 
activity     
8017376  -1.21 0.014 sphingosine_kinase_[Ho
mo_sapiens] 
P: sphingosine metabolic 
process    P: sphingoid 
catabolic process    P: 
positive regulation of 
smooth muscle contra...    P: 
positive regulation of 
progression through ...    P: 
positive regulation of 
fibroblast proliferation    P: 
positive regulation of cell 
migration    P: positive 
regulation of cell growth    
P: positive regulation of 
angiogenesis    P: G-protein 
coupled receptor protein 
signalin...    P:calcium-
mediated signaling    P:anti-
apoptosis     
IPI00103869.1 CTTNBP2 1.22 0.015 Cortactin-
binding_protein_2 
 
IPI00060544.3 DDIT4L -1.12 0.015 DNA-damage-
inducible_transcript_4-
like 
 
IPI00444179.2 LSDP5 1.27 0.015 PREDICTED:_similar_t
o_lipid_droplet_associat
ed_protein 
 
IPI00787962.1 LRRC48 -1.18 0.015 PREDICTED:_similar_t
o_leucine_rich_repeat_c
ontaining_48 
 
IPI00328156.8 MAOB -1.18 0.015 Amine_oxidase_[flavin-
containing]_B 
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IPI00003926.2 CLN8 -1.17 0.015 Protein_CLN8 P:protein catabolic process    
P:phospholipid metabolic 
process    P:nervous system 
development    P:negative 
regulation of proteolysis    
P:lipid transport    
P:cholesterol metabolic 
process    P:ceramide 
biosynthetic process     
IPI00064462.2 ABHD13 -1.17 0.015 hypothetical_protein_L
OC84945 
 
IPI00152637.1 ADAMTS15 -1.25 0.016 ADAMTS-15_precursor  
IPI00152627.4 C11orf30 -1.17 0.016 Chromosome_11_open_
reading_frame_30 
 
IPI00549189.3 THOP1 -1.17 0.016 Thimet_oligopeptidase  
IPI00745599.1 NBLA00301 -1.13 0.016 Similar_to_Heart-
_and_neural_crest_deriv
atives-
expressed_protein_2 
 
IPI00180515.2 NBEAL2 1.14 0.016 CDNA_FLJ35552_fis,_
clone_SPLEN2004346 
 
IPI00020668.4 UTF1 -1.13 0.016 UTF1 P: positive regulation of 
transcription from R...     
IPI00023287.4 NEDD4L -1.13 0.016 Isoform_4_of_E3_ubiqu
itin-
protein_ligase_NEDD4-
like_protein 
P:water homeostasis    
P:sodium ion transport    
P:response to metal ion    
P:regulation of protein 
catabolic process    P:protein 
ubiquitination    P:positive 
regulation of endocytosis    
P:excretion    P:cellular 
sodium ion homeostasis     
IPI00104698.5  1.16 0.017 31_kDa_protein  
IPI00384597.1 PHC2 -1.15 0.017 Polyhomeotic_2_homol
og 
 
IPI00151888.4 DOCK9 -1.11 0.017 Isoform_1_of_Dedicator
_of_cytokinesis_protein
_9 
 
IPI00787064.1  1.16 0.018 PREDICTED:_similar_t
o_statin-like 
 
IPI00032056.3 C17orf85 -1.14 0.018 ELG_protein  
IPI00017800.2 ABCA3 -1.14 0.018 ATP-
binding_cassette_sub-
family_A_member_3 
P:transport    P:response to 
drug     
IPI00033054.4 CTDSPL2 -1.21 0.019 CTD_(carboxy-
terminal_domain,_RNA
_polymerase_II,_polype
ptide_A)_small_phospha
tase_like_2 
 
IPI00398169.2 LOC165186 -1.13 0.019 CDNA_FLJ43756_fis,_
clone_TESTI2045920 
 
IPI00465243.4 TMC4 -1.13 0.019 Transmembrane_channe
l-like_protein_4 
 
6912632  1.15 0.019 rearranged_L-
myc_fusion_sequence_[
Homo_sapiens] 
 
IPI00177655.2 LRRC42 -1.13 0.019 51_kDa_protein  
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IPI00162549.2 SP110 -1.32 0.019 SP110_nuclear_body_pr
otein_isoform_c 
 
IPI00009737.1 RRAGD 1.13 0.019 Isoform_1_of_Ras-
related_GTP-
binding_protein_D 
 
5911869  DKFZp434
E066 
1.25 0.019 hypothetical_protein_[H
omo_sapiens] 
 
IPI00171407.4 STXBP5 1.15 0.019 Isoform_1_of_Syntaxin-
binding_protein_5 
 
IPI00640568.1 ALDOA 1.23 0.019 15_kDa_protein  
IPI00020002.3 CNO -1.20 0.020 Protein_cappuccino_ho
molog 
 
IPI00293592.2 C16orf71 1.11 0.020 hypothetical_protein_L
OC146562 
 
IPI00000375.5 CAPS2 1.15 0.020 Isoform_2_of_Calcypho
sin-2 
 
IPI00478959.2 SPATA13 1.11 0.020 OTTHUMP0000001812
7 
 
IPI00026546.1 PAFAH1B2 1.11 0.020 Platelet-
activating_factor_acetyl
hydrolase_IB_subunit_b
eta 
P:lipid metabolic process     
IPI00386113.1 C20orf59 1.13 0.021 Hypothetical_protein_F
LJ23412 
 
IPI00218013.6 SGOL2 -1.21 0.021 Isoform_2_of_Shugoshi
n-like_2 
 
IPI00073357.1 FBXO4 1.11 0.021 Isoform_1_of_F-
box_only_protein_4 
P:protein ubiquitination     
IPI00027627.1 TNFAIP8 1.11 0.021 MDC-3.13_isoform_2 P:negative regulation of 
anti-apoptosis     
IPI00745619.1 FLJ27502 -1.20 0.021 Similar_to_37LRP/p40  
IPI00289334.1 FLNB -1.21 0.021 Isoform_1_of_Filamin-
B 
P:signal transduction    
P:cytoskeletal anchoring    
P:actin cytoskeleton 
organization and biogenesis    
IPI00216856.3 ANKMY2 1.13 0.021 Ankyrin_repeat_and_M
YND_domain-
containing_protein_2 
 
IPI00419908.3 GPR179 -1.20 0.022 Probable_G-
protein_coupled_recepto
r_179_precursor 
 
IPI00009146.3 TRAFD1 1.11 0.022 Fln29  
IPI00003905.1 SLC2A2 -1.19 0.023 Solute_carrier_family_2,
_facilitated_glucose_tra
nsporter_member_2 
P:glucose transport    
P:carbohydrate metabolic 
process     
IPI00160622.1 CEP250 1.35 0.023 Isoform_1_of_Centroso
me-
associated_protein_CEP
250 
P:regulation of centriole-
centriole cohesion    
P:mitotic cell cycle     
IPI00007425.1 DSC1 -1.22 0.023 desmocollin_1_isoform_
Dsc1b_preproprotein 
P:homophilic cell adhesion     
IPI00030941.5 TSPAN3 -1.12 0.023 Tetraspanin-3  
7020225  1.12 0.023 unnamed_protein_produ
ct_[Homo_sapiens] 
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IPI00289116.2 GPAM -1.21 0.023 Hypothetical_protein_F
LJ23960 
P:phospholipid biosynthetic 
process     
IPI00026663.2 ALDH1A3 -1.20 0.023 Aldehyde_dehydrogenas
e_1A3 
P:lipid metabolic process    
P:alcohol metabolic process    
IPI00006640.3 SERPINI2 1.11 0.023 Serpin_I2_precursor P:cell motility     
IPI00642716.3 MYH7B -1.20 0.023 OTTHUMP0000003072
0 
 
IPI00217690.1 MGC42105 -1.10 0.023 Serine/threonine-
protein_kinase_NIM1 
P:protein amino acid 
phosphorylation     
IPI00007626.1 KCNJ4 -1.20 0.023 Inward_rectifier_potassi
um_channel_4 
P:potassium ion transport     
IPI00746049.1 ANKRD30B -1.14 0.023 Similar_to_Breast_cance
r_antigen_NY-BR-1.1 
 
52693921 SHC1 1.22 0.023 SHC_(Src_homology_2
_domain_containing)_tr
ansforming_protein_1_is
oform_p66Shc_[Homo_
sapiens] 
P: regulation of epidermal 
growth factor recep...    
P:positive regulation of 
mitosis    P:positive 
regulation of cell 
proliferation    P:activation 
of MAPK activity     
IPI00021326.4 SHC1 1.22 0.023 SHC_(Src_homology_2
_domain_containing)_tr
ansforming_protein_1 
P:intracellular signaling 
cascade     
IPI00217696.3 PPIL6 -1.30 0.023 Peptidyl-prolyl_cis-
trans_isomerase 
 
IPI00383200.1  1.13 0.023 HSPC271_(Fragment)  
IPI00005559.1 NOD2 1.10 0.023 Isoform_1_of_Caspase_
recruitment_domain-
containing_protein_15 
P: protein oligomerization    
P: positive regulation of 
interleukin-1 beta s...    P: 
positive regulation of I-
kappaB kinase/NF-k...    
P:detection of muramyl 
dipeptide    P:detection of 
bacterium    P:defense 
response to bacterium    
P:activation of NF-kappaB 
transcription factor     
IPI00418236.1 FIGLA 1.10 0.023 Factor_in_the_germline
_alpha 
P:oocyte development     
IPI00103595.2 CEP350 1.11 0.023 Centrosome-
associated_protein_350 
 
IPI00739552.2  1.18 0.023 Pseudogene_candidate  
IPI00006714.2 PTPN13 -1.19 0.024 Isoform_3_of_Tyrosine-
protein_phosphatase_no
n-receptor_type_13 
P:protein amino acid 
dephosphorylation     
IPI00162733.2 KCNC2 1.10 0.024 Kv3.2d_voltage-
gated_potassium_channe
l 
 
8926561  -1.18 0.024 AF274840_1_T_cell_rec
eptor_beta_chain_[Hom
o_sapiens] 
 
IPI00017974.1 9-Sep -1.20 0.024 CDNA_FLJ12190_fis,_
clone_MAMMA100084
2 
 
IPI00012504.2 ZNF44 -1.20 0.024 zinc_finger_protein_44  
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IPI00472977.2 USP37 1.09 0.024 Ubiquitin_carboxyl-
terminal_hydrolase_37 
 
IPI00024074.1 CCDC69 -1.28 0.025 CDNA_FLJ13705_fis,_
clone_PLACE2000302 
 
IPI00428657.1 GIGYF1 1.10 0.025 PERQ_amino_acid_rich,
_with_GYF_domain_1 
 
IPI00302010.5 FLJ20309 -1.13 0.026 Hypothetical_protein_F
LJ20309 
 
IPI00374484.4 LOC731911 1.20 0.027 PREDICTED:_hypotheti
cal_protein 
 
IPI00289877.7 TOX3 -1.14 0.027 PREDICTED:_similar_t
o_trinucleotide_repeat_c
ontaining_9_isoform_4 
 
IPI00786918.1 FAM82B -1.17 0.027 hypothetical_protein_L
OC51115 
 
IPI00175977.3 TDRD5 1.09 0.027 CDNA_FLJ45446_fis,_
clone_BRSSN2015497 
 
IPI00384202.3 JMJD1C 1.09 0.027 Isoform_1_of_Probable_
JmjC_domain-
containing_histone_dem
ethylation_protein_2C 
P:regulation of transcription, 
DNA-dependent     
IPI00217481.2 GPR126 1.48 0.027 Developmentally_regula
ted_G-protein-
coupled_receptor_beta_
1 
P: G-protein coupled 
receptor protein signalin...     
IPI00382872.1 DUX4 1.21 0.027 Facioscapulohumeral_m
uscular_dystrophy 
P:regulation of transcription, 
DNA-dependent     
IPI00099871.1 MRPL40 -1.19 0.027 39S_ribosomal_protein_
L40,_mitochondrial_pre
cursor 
P:anatomical structure 
morphogenesis     
IPI00025100.1 BCKDHA -1.13 0.027 2-
oxoisovalerate_dehydro
genase_alpha_subunit,_
mitochondrial_precursor 
P:branched chain family 
amino acid catabolic ...     
IPI00304742.4 STK10 -1.13 0.027 113_kDa_protein P:protein amino acid 
phosphorylation     
IPI00744046.1  -1.13 0.027 Similar_to_Glutamate_r
eceptor_delta-
1_subunit_precursor 
 
IPI00299095.2 SNX2 -1.10 0.027 Sorting_nexin-2 P:endocytosis     
IPI00646354.1 PTAR1 1.15 0.027 OTTHUMP0000002143
6 
P:protein amino acid 
prenylation     
IPI00384443.4 BRD9 -1.21 0.028 Sarcoma_antigen_NY-
SAR-29 
 
IPI00060310.4 PLD4 1.21 0.028 phospholipase_D_family
,_member_4 
 
IPI00163782.2  1.18 0.028 Isoform_2_of_Far_upstr
eam_element-
binding_protein_1 
 
IPI00005210.1 CETN3 1.10 0.028 Centrin-3 P:centrosome cycle     
IPI00017596.2 MAPRE1 -1.13 0.028 Microtubule-
associated_protein_RP/E
B_family_member_1 
P: regulation of progression 
through cell cycle    P: 
negative regulation of 
microtubule polymeri...    
P:cell proliferation     
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20151073  -1.23 0.029 A_Chain_A,_Human_Ti
ssue_Transglutaminase_
In_Gdp_Bound_Form 
 
34527259  1.19 0.029 unnamed_protein_produ
ct_[Homo_sapiens] 
 
10432782 TES -1.19 0.029 unnamed_protein_produ
ct_[Homo_sapiens] 
 
IPI00033036.1 METAP2 1.08 0.029 Methionine_aminopepti
dase_2 
P:protein processing    
P:peptidyl-methionine 
modification    P:N-terminal 
protein amino acid 
modification     
IPI00394857.1 EFCAB5 -1.33 0.029 CDNA_FLJ46247_fis,_
clone_TESTI4021129 
 
IPI00023757.2 RPGR 1.09 0.030 Isoform_1_of_X-
linked_retinitis_pigment
osa_GTPase_regulator 
P:visual perception    
P:intracellular protein 
transport     
IPI00221224.4 ANPEP 1.13 0.031 Aminopeptidase_N  
IPI00034099.3 RBM35B 1.07 0.031 Hypothetical_protein_F
LJ21918 
 
IPI00006093.2 FAM38A -1.16 0.031 Protein_FAM38A  
IPI00604745.2 MAPK13 1.14 0.031 MAPK13_protein_varia
nt 
P:protein amino acid 
phosphorylation     
IPI00001348.5 SFI1 1.24 0.031 spindle_assembly_associ
ated_Sfi1_homolog_isof
orm_a 
 
IPI00255653.4 ATP11A -1.13 0.033 Probable_phospholipid-
transporting_ATPase_IH 
 
IPI00299024.8 BASP1 1.10 0.033 Brain_acid_soluble_prot
ein_1 
 
IPI00103586.5 CPA5 -1.13 0.033 Isoform_1_of_Carboxyp
eptidase_A5_precursor 
 
IPI00176532.1 JPH2 1.19 0.033 Isoform_1_of_Junctophi
lin-2 
 
IPI00220956.2 MTMR1 -1.19 0.033 Isoform_1A_of_Myotub
ularin-related_protein_1 
 
IPI00303401.4 C1orf75 -1.10 0.034 FLJ10874_protein  
IPI00015697.3 C13orF14 -1.19 0.034 OTTHUMP0000001849
5 
 
48146179 IFIT5 -1.08 0.035 IFIT5_[Homo_sapiens]  
IPI00375803.3 GON4L -1.19 0.036 Isoform_1_of_GON-4-
like_protein 
 
IPI00012322.1 PRKG2 -1.11 0.036 cGMP-
dependent_protein_kinas
e_2 
P:signal transduction    
P:regulation of progression 
through cell cycle    
P:protein amino acid 
phosphorylation     
IPI00032063.5 LRP1B -1.21 0.036 CDNA_FLJ30101_fis,_
clone_BNGH41000118,
_highly_similar_to_Ho
mo_sapiens_low_densit
y_lipoprotein_receptor_r
elated_protein-
deleted_in_tumor_(Frag
ment) 
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IPI00329591.3 RMND1 -1.18 0.037 Isoform_1_of_Protein_C
6orf96 
 
IPI00215827.1 AMPD2 -1.12 0.038 Isoform_Ex1B-
3_of_AMP_deaminase_
2 
P:purine nucleotide 
metabolic process     
IPI00017469.1 SPR -1.12 0.038 Sepiapterin_reductase P:tetrahydrobiopterin 
biosynthetic process    
P:nitric oxide biosynthetic 
process    P:electron 
transport     
IPI00167903.5 ZNF555 -1.19 0.039 Isoform_2_of_Zinc_fing
er_protein_555 
 
IPI00010604.4 PLCE1 1.13 0.040 Phospholipase_C,_epsil
on_1 
 
IPI00154489.1 LOC146325 -1.19 0.040 Hypothetical_protein_RJ
D1 
 
IPI00640218.1 ZNF709 -1.19 0.040 Zinc_finger_protein_709  
IPI00241409.8 FAM21B -1.17 0.040 PREDICTED:_similar_t
o_CG16742-
PA,_isoform_A_isoform
_1 
 
IPI00398791.1 LOC375127 -1.21 0.040 Hypothetical_protein_F
LJ26056 
 
IPI00009329.1 UTRN 1.13 0.040 Utrophin P:muscle development    
P:muscle contraction     
IPI00177519.2 RBM24/RB
M38/RNPC1 
1.22 0.040 24_kDa_protein  
22760635 SHC1 -1.12 0.040 unnamed_protein_produ
ct_[Homo_sapiens] 
 
IPI00011932.7 HSPA12A 1.12 0.040 PREDICTED:_similar_t
o_Heat_shock_70_kDa_
protein_12A_isoform_1 
 
IPI00008998.1 PTPLAD1 -1.15 0.040 HSPC121  
IPI00148061.3 LDHAL6A 1.12 0.040 L-
lactate_dehydrogenase_
A-like_6A 
 
IPI00240059.3 TMCC3 -1.15 0.041 Transmembrane_and_co
iled-
coil_domains_protein_3 
 
IPI00329637.2 C1orf26 -1.14 0.041 Uncharacterized_protein
_C1orf26 
 
IPI00167788.1 C16orf81 -1.12 0.042 CDNA_FLJ36701_fis,_
clone_UTERU2009147 
 
IPI00168501.3 ZC3H14 1.11 0.042 nuclear_protein_UKp68
_isoform_3 
 
IPI00025276.1 TNXB 1.13 0.043 Isoform_XB_of_Tenasci
n-X_precursor 
P:elastic fiber assembly    
P:collagen metabolic 
process    P:cell adhesion    
P:actin cytoskeleton 
organization and biogenesis    
IPI00015826.1 ABCB10 -1.19 0.043 ATP-
binding_cassette_sub-
family_B_member_10,_
mitochondrial_precursor 
P:transport     
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IPI00419849.3 C19orf2 -1.11 0.043 RNA_polymerase_II_su
bunit_5-
mediating_protein 
P: response to virus    P: 
regulation of transcription 
from RNA polyme...     
IPI00738733.2 LOC643491 1.19 0.045 PREDICTED:_similar_t
o_Golgin_subfamily_A_
member_2 
 
IPI00291755.5 NUP210 -1.19 0.045 206_kDa_protein  
627616  1.12 0.047 PH0229_T-
cell_receptor_Vb_CDR3
,_carrier_Vb_17.sbt_-
_human_(fragment) 
 
IPI00007993.4 HIC1 -1.11 0.048 Isoform_1_of_Hypermet
hylated_in_cancer_1_pr
otein 
P:regulation of transcription, 
DNA-dependent    
P:multicellular organismal 
development     
IPI00021034.1 COL4A1 -1.20 0.048 Collagen_alpha-
1(IV)_chain_precursor 
 
29646899  -1.16 0.048 T_cell_receptor_beta_ch
ain_[Homo_sapiens] 
 
IPI00738065.1 LOC652627 -1.11 0.048 PREDICTED:_similar_t
o_dead_end_homolog_1 
 
IPI00410214.1 BPNT1 -1.16 0.050 Isoform_1_of_3'(2'),5'-
bisphosphate_nucleotida
se_1 
P: nucleobase, nucleoside, 
nucleotide and nucl...    
P:nervous system 
development     
IPI00513975.2 PRRT1 1.16 0.050 Chromosome_6_open_r
eading_frame_31 
 
 
• Q-Values for both protein identification and quantification are the minimal q-
values from all samples. 
• Fold change= Mean_T / Mean _C when Mean_T ≥ Mean_C (up-regulation) 
Negative values mean down-regulation in the cancer plasma sample. 
• All protein with significant changes were annotated and categorized based on their 
biological function with Gene Ontology. 
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Appendix 2: Luminal B (P4) enriched proteins with significant changes     
Protein_ID  Annotation q_H_P4 FC_H_P4 
IPI00477597.1 Isoform_1_of_Haptoglobin-related_protein_precursor 7.52E-05 1.96 
IPI00431645.1 HP_protein 7.52E-05 2.12 
IPI00478493.3 HP_protein 7.52E-05 2.04 
IPI00641737.1 Haptoglobin_precursor 7.52E-05 2.07 
306882 haptoglobin_precursor 7.52E-05 2.06 
IPI00465006.1 Hypothetical_protein_DKFZp686D19113 0.0004134 2.03 
IPI00021727.1 C4b-binding_protein_alpha_chain_precursor 0.0023582 1.31 
IPI00025862.1 C4b-binding_protein_beta_chain_precursor 0.0037023 1.26 
229386 720005A_protein,alpha1_acid_glyco 0.0037023 2.05 
IPI00294004.1 Vitamin_K-dependent_protein_S_precursor 0.0038465 1.27 
IPI00032056.3 ELG_protein 0.0059168 -1.69 
IPI00431656.4 Isoform_2_of_Alpha-1-antichymotrypsin_precursor 0.0064549 1.33 
IPI00022429.3 Alpha-1-acid_glycoprotein_1_precursor 0.0064549 1.77 
48425723 E_Chain_E,_Structure_Of_Human_Transferrin_Receptor-
Transferrin_Complex 
0.0064549 -1.56 
IPI00025204.1 CD5_antigen-like_precursor 0.006576 -1.26 
IPI00550991.2 Isoform_1_of_Alpha-1-antichymotrypsin_precursor 0.006576 1.28 
225769 1313184C_chymotrypsin_inhibitor 0.006576 1.29 
IPI00021364.1 Properdin_precursor 0.006576 -1.2 
IPI00022392.1 Complement_C1q_subcomponent_subunit_A_precursor 0.0089154 -1.21 
126608 LYSOZYME_Spiked_Standard_(HEN) 0.0089154 -1.17 
IPI00011264.1 Complement_factor_H-related_protein_1_precursor 0.0089154 1.27 
IPI00022463.1 Serotransferrin_precursor 0.0089154 -1.4 
7245523 A_Chain_A,_Human_Serum_Transferrin 0.0133428 -1.4 
IPI00020091.1 Alpha-1-acid_glycoprotein_2_precursor 0.0158175 1.62 
IPI00216438.3 Solute_carrier_family_12_member_3 0.0163767 1.47 
IPI00022391.1 Serum_amyloid_P-component_precursor 0.0168972 1.3 
IPI00027507.1 Complement_factor_H-related_protein_3_precursor 0.0172369 1.49 
IPI00785067.1 Hypothetical_protein 0.0173138 -1.42 
IPI00642716.3 OTTHUMP00000030720 0.0173138 -1.78 
IPI00015697.3 OTTHUMP00000018495 0.0173138 -1.81 
IPI00218013.6 Isoform_2_of_Shugoshin-like_2 0.0173138 -1.83 
IPI00164672.5 mRNA_decapping_enzyme_1A 0.0173138 -1.99 
IPI00301072.3 Small_conductance_calcium-
activated_potassium_channel_protein_2 
0.0173138 -1.41 
IPI00441894.1 Hypothetical_protein_FLJ24000 0.0173138 1.81 
IPI00032328.1 Isoform_HMW_of_Kininogen-1_precursor 0.0236039 -1.14 
IPI00027462.1 Protein_S100-A9 0.0250229 1.37 
21707947 Leucine-rich_alpha-2-glycoprotein_1_[Homo_sapiens] 0.0279059 1.35 
IPI00007047.1 Protein_S100-A8 0.0279853 1.43 
IPI00167093.4 Complement_factor_H-related_1 0.0283429 1.32 
IPI00021891.5 Isoform_Gamma-B_of_Fibrinogen_gamma_chain_precursor 0.0289841 1.33 
IPI00654888.2 Kallikrein_B,_plasma_(Fletcher_factor)_1 0.0298312 -1.13 
IPI00006987.1 ATP-dependent_RNA_helicase_DDX24 0.0310875 1.47 
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1575607 FUSE_binding_protein_2_[Homo_sapiens] 0.0310875 -1.7 
IPI00001611.1 Isoform_1_of_Insulin-like_growth_factor_II_precursor 0.0310875 -1.23 
IPI00030013.1 Homeobox_protein_SIX3 0.0310875 -1.65 
IPI00018583.3 Hyaluronan_binding_protein_4 0.0310875 1.23 
IPI00742996.1 IMP_dehydrogenase/GMP_reductase_family_protein 0.0311546 -1.65 
IPI00303963.1 Complement_C2_precursor_(Fragment) 0.0323115 1.11 
IPI00027410.1 Platelet_glycoprotein_V_precursor 0.0357933 -1.42 
IPI00445774.1 CDNA_FLJ43404_fis,_clone_OCBBF2017516 0.0382753 -1.5 
IPI00020996.3 Insulin-like_growth_factor-
binding_protein_complex_acid_labile_chain_precursor 
0.0390292 -1.16 
IPI00298497.3 Fibrinogen_beta_chain_precursor 0.0390292 1.35 
223002 0401173A_fibrin_beta 0.0390292 1.36 
IPI00183706.3 KIF19_protein_(Fragment) 0.04351 1.36 
IPI00022395.1 Complement_component_C9_precursor 0.0440995 1.17 
IPI00398021.1 27_kDa_protein 0.0452365 1.4 
IPI00215894.1 Isoform_LMW_of_Kininogen-1_precursor 0.0453133 -1.13 
IPI00292218.3 Hepatocyte_growth_factor-like_protein_precursor 0.0453133 1.23 
IPI00004656.1 Beta-2-microglobulin_precursor 0.0465936 -1.14 
IPI00018305.3 Insulin-like_growth_factor-binding_protein_3_precursor 0.0480621 -1.24 
IPI00787962.1 PREDICTED:_similar_to_leucine_rich_repeat_containing_48 0.0480621 -1.34 
IPI00394851.1 hypothetical_protein_LOC346689 0.0480621 -1.27 
IPI00788062.1 PREDICTED:_similar_to_protein_immuno-
reactive_with_anti-PTH_polyclonal_antibodies 
0.0484759 1.34 
IPI00168529.2 hypothetical_protein_LOC126859_isoform_2 0.0485396 -1.46 
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Appendix 3: Proteins with significant changes enriched in Basal type (P1) 
Protein_ID  Annotation q_H_P1 FC_H_P1 
IPI00465006.1 Hypothetical_protein_DKFZp686D19113 0.03681419 1.43 
IPI00020091.1 Alpha-1-acid_glycoprotein_2_precursor 0.037612552 1.41 
IPI00431645.1 HP_protein 0.033220081 1.41 
IPI00027507.1 Complement_factor_H-related_protein_3_precursor 0.025613945 1.41 
IPI00478493.3 HP_protein 0.033220081 1.4 
306882 haptoglobin_precursor 0.033220081 1.39 
IPI00641737.1 Haptoglobin_precursor 0.033220081 1.39 
IPI00477597.1 Isoform_1_of_Haptoglobin-
related_protein_precursor 
0.033220081 1.37 
IPI00216438.3 Solute_carrier_family_12_member_3 0.03681419 1.31 
IPI00025862.1 C4b-binding_protein_beta_chain_precursor 0.001962815 1.22 
IPI00019399.1 Serum_amyloid_A-4_protein_precursor 0.033220081 1.19 
IPI00021727.1 C4b-binding_protein_alpha_chain_precursor 0.025613945 1.19 
37947 unnamed_protein_product_[Homo_sapiens] 0.033220081 1.18 
IPI00023014.1 von_Willebrand_factor_precursor 0.033220081 1.18 
IPI00026314.1 Isoform_1_of_Gelsolin_precursor 0.047272606 -1.15 
IPI00299040.1 Polycystin-2 0.037802977 -1.16 
IPI00001611.1 Isoform_1_of_Insulin-
like_growth_factor_II_precursor 
0.03681419 -1.17 
IPI00025204.1 CD5_antigen-like_precursor 0.025613945 -1.2 
IPI00022431.1 Alpha-2-HS-glycoprotein_precursor 0.04335994 -1.22 
IPI00218539.3 Isoform_B_of_Collagen_alpha-
1(XI)_chain_precursor 
0.042958593 -1.26 
IPI00301072.3 Small_conductance_calcium-
activated_potassium_channel_protein_2 
0.03681419 -1.28 
IPI00785067.1 Hypothetical_protein 0.03681419 -1.3 
IPI00032056.3 ELG_protein 0.04736649 -1.32 
IPI00019451.3 MRG-binding_protein 0.04736649 -1.32 
8885790 AF146692_1_filamin_2_[Homo_sapiens] 0.03681419 -1.35 
IPI00328762.4 ATP_binding_cassette,_sub-
family_A_(ABC1),_member_13 
0.040977469 -1.35 
IPI00465430.5 70_kDa_protein 0.04736649 -1.36 
IPI00010700.2 Isoform_1_of_Large_proline-rich_protein_BAT2 0.037802977 -1.36 
1017427 elastic_titin_[Homo_sapiens] 0.04736649 -1.37 
IPI00445774.1 CDNA_FLJ43404_fis,_clone_OCBBF2017516 0.03681419 -1.37 
IPI00742996.1 IMP_dehydrogenase/GMP_reductase_family_protein 0.03681419 -1.47 
IPI00218013.6 Isoform_2_of_Shugoshin-like_2 0.03681419 -1.5 
IPI00642716.3 OTTHUMP00000030720 0.03681419 -1.51 
IPI00015697.3 OTTHUMP00000018495 0.03681419 -1.58 
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Appendix 4: Significance differences among Luminal type B and Basal 
Protein_ID  Annotation q_H_p4 FC_p1_p4 
IPI00431645.1 HP_protein 7.52E-05 1.50 
IPI00641737.1 Haptoglobin_precursor 7.52E-05 1.49 
306882 haptoglobin_precursor 7.52E-05 1.48 
IPI00478493.3 HP_protein 7.52E-05 1.46 
IPI00465006.1 Hypothetical_protein_DKFZp686D19113 0.000413398 1.42 
IPI00477597.1 Isoform_1_of_Haptoglobin-related_protein_precursor 7.52E-05 1.43 
IPI00006987.1 ATP-dependent_RNA_helicase_DDX24 0.031087485 1.36 
IPI00007047.1 Protein_S100-A8 0.027985303 1.42 
IPI00398021.1 27_kDa_protein 0.045236465 1.41 
IPI00027462.1 Protein_S100-A9 0.025022886 1.33 
IPI00788062.1 PREDICTED:_similar_to_protein_immuno-
reactive_with_anti-PTH_polyclonal_antibodies 
0.048475938 1.31 
IPI00167093.4 Complement_factor_H-related_1 0.028342855 1.29 
IPI00011264.1 Complement_factor_H-related_protein_1_precursor 0.00891538 1.22 
IPI00292218.3 Hepatocyte_growth_factor-like_protein_precursor 0.045313251 1.26 
IPI00215894.1 Isoform_LMW_of_Kininogen-1_precursor 0.045313251 -1.12 
IPI00004656.1 Beta-2-microglobulin_precursor 0.046593554 -1.15 
IPI00032328.1 Isoform_HMW_of_Kininogen-1_precursor 0.0236039 -1.13 
IPI00021364.1 Properdin_precursor 0.006576016 -1.14 
IPI00394851.1 hypothetical_protein_LOC346689 0.048062145 -1.27 
IPI00787962.1 PREDICTED:_similar_to_leucine_rich_repeat_contain
ing_48 
0.048062145 -1.30 
IPI00022463.1 Serotransferrin_precursor 0.00891538 -1.26 
48425723 E_Chain_E,_Structure_Of_Human_Transferrin_Recept
or-Transferrin_Complex 
0.00645493 -1.32 
IPI00030013.1 Homeobox_protein_SIX3 0.031087485 -1.69 
 
  
 
 
        72 
References:  
1. Jemal A, et al. Cancer statistics. CA Cancer J Clin. 2006, 56(2):106-30. 
2. Retrieved May 2008 from 
www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the _key_statistics. 
3. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2004, 
54(8):18-29. 
4. Wulfkuhle JD, et al. Proteomic applications for the early detection of cancer. Nature 
reviews/cancer. April 2003, 3(4):267-75. 
5. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden. Globocan  
Int J Cancer. 2001, 94:153-56. 
6. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin. 
2005, 55:74-108. 
7. Retrieved May 2008 from 
http://www.cancer.org/docroot/CRI/content/CRI_2_4_3X_Can_breast_cancer_be_fo
und_early_5.asp. Can breast cancer be found early?    
8. Antman K, Shea S. Screening mammography under age 50. JAMA. 1999, 281:1470-
1472. 
9. Hondermarck H, et al. Breast Cancer when proteomics challenges biological 
complexity. Molecular & Cellular Proteomics. 2003, 2:281-291. 
10. Retrieved December 2007 from http://www.enotalone.com/article/8598.html. 
Limitations of Mammography, When to Get a Mammogram? 
  
 
 
        73 
11. Sorlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor   
subclasses with clinical implication. Proc Natl Acad Sci USA. 2001, 98(19):10869-
74. 
12. Srinivas PR, Kramer BS, Srivastava S. Trends in biomarker research for cancer 
detection. Lancet Oncol. 2001, 2:698-704. 
13. Pothur R, et al. Proteomics for cancer biomarker discovery. Clinic Chemistry. 2002, 
48-8: 1160-69. 
14. Polanski M, Anderson N.L. A List of Candidate Cancer Biomarkers. Biomarker 
Insight. 2006, 5:21-48. 
15. Mor G, Visintin I, Lai Y. Serum protein markers for early detection of ovarian cancer. 
PNAS. 2005, Vol. 102 No.21:7677-82. 
16. Pothur R, et al. Proteomics for cancer biomarker discovery. Clinic Chemistry. 2002, 
48-8: 1160-69. 
17. O’Farrell PH et al. High resolution two-dimensional electrophoresis of proteins. J. 
Biochem 1975, 250:4007-4021. 
18. Gygi SP, et al. Quantitative analysis of complex protein mixtures using isotope-coded 
affinity tags. Natl Biotech. 1999, 17:994-999. 
19. Wei Y, Sharon S. Mass spectrometry-based quantitative proteomic profiling. 
Briefings in functional genomics and proteomics. May 2005, 4(1):27-38. 
20. Higgs R, Knierman M. Comprehensive Label-Free Method for the Relative 
Quantification of Proteins from Biological Samples. Journal of Proteome Research. 
2005, 4:1442-50. 
  
 
 
        74 
21. Fitzpatrick D, You JS. Searching for potential biomarkers of cisplatin resistance in 
human ovarian cancer using a label-free LC/MS-based protein quantification method. 
Proteomics Clin. April 2007, (1):246-63. 
22. Visintin G, Lai Y. Serum protein markers for early detection of ovarian cancer. 
PNAS. May 24 2005, 102 (21):7677-82. 
23. Hinerfeld D, et al. Serum/Plasma Depletion with Chicken Immunoglobulen Y 
Antibodies for Proteomic Analysis from Multiple Mammalian Species. Journal of 
biomolecular techniques. 2004, 15(3):3721-3732.  
24. Petricoin E, Liotta L. The vision for a new diagnostic paradigm. ClinChem. 2003, 
49:1276-78. 
25. Huang L. Immunoaffinity separation of plasma proteins by IgY microbeads: meeting 
the needs of proteomic sample preparation and analysis. Proteomics 2005, 5:3314-28. 
26. Retrieved April 2008 from http://www.genwaybio.com/gw_file.php?fid=2026 
27. Hale JE, Butler JP, Gelfanova V, You J S, Knierman M D. A simplified procedure for 
the reduction and alkylation of cysteine residues in proteins prior to proteolytic 
digestion and mass spectral analysis. Anal. Biochem. 2004, 333:174-81. 
28. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization 
methods for high density oligonucleotide array data based on variance and bias. 
Bioinformatics 2003, 19:185-93.  
29. Carr S, Aebersold R, Baldwin M, Burlingame A, Clauser K, Nesvizhskii A. The need 
for guidelines in publication of peptide and protein identification data: Working 
Group on Publication Guidelines for Peptide and Protein Identification Data. 
Molecular & Cellular Proteomics 2004, 3:531-33.  
  
 
 
        75 
30. Retrieved May, 2008 from http://proteomics.cancer.gov/programs/CPTAC. 
31. Retrieved September, 2007 from http://www.pir.uniprot.org. 
32. Retrieved September, 2007 from http://www.geneontology.org. 
33. Bradford M, et al. A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding anal. Biochem 
1976, 72:248-54. 
34. Onitilo AA, Engel J. Breast cancer subtypes based on ER/PR and HER2 expression: 
A population-based experience. J Clin Oncol. 2008, 26: 325-332     
35. Sorlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor 
subclasses with clinical implications. Proc. Natl. Acad. Sci. USA  2001, 98(19):2639-
48. 
36. Retrieved September, 2008 from http://www.pwc.com/techforecast/pdfs/pharmaco-
wb-x.pdf. The emerging pharmacogenomics revolution. Personalized Medicine. 
37. Wagner K, Hemminki K. The insulin-like growth factor-1 pathway mediator genes: 
SHC1 Met 300Val shows a protective effect in breast cancer. Carcinogenesis. 2004, 
25: 2473-2478 
38. Schmid K, et al. Plasma proteins, structure, function and genetic control. Academic 
Press.1975, 1:183-288. 
39. Irmak S, Tilki D. Stage-dependent increase of orosomucoid and zinc-alpha-
glycoprotein in urinary bladder cancer. Proteomics 2005, 5:4296-304. 
40. Surmacz E, et al. Function of the IGF-1 receptor in breast cancer. J. Mammary Gland 
Biol. Neoplasina. 2000, 5:95-105. 
  
 
 
        76 
41. Ravichandran K, et al. Signaling via SHC family adapter proteins. Oncogene. 2001, 
20:6322-30. 
42. Stevenson, LE,  Frackelton, ARJr. Constitutively tyrosine phosphorylated p52 Shc in 
breast cancer cells: Correlatin with ErbB2 and p66 Shc expression. Breast Cancer.  
1998, 49:119-28. 
43. Sivaraman V S, Wang H. Hyperexpression of mitogen-activated protein kinase in 
human breast cancer. J. Clin. Invest. 1997, 99:1478-83. 
44. Saito S, Murayama Y. Haptoglobin-beta chain defined by monoclonal antibody RM2 
as a novel serum marker for prostate cancer. Intl. J. Cancer. 2008 Aug 1, 123(3):633-
40. 
45. Ruosahti E, et al. The Walte Herbert Lecture. Control of cell motility and tumour 
invasion by extracellalar matrix interactions. Br. J. Cancer. 1992, 66:239-42.  
46. Duband  J L, et al. The instructive role of fibronectins in cell migrations during 
embryonic development. Ann. New York Acad. Sci. 1990, 588:273-80. 
47. Balbona K, et al, Tran H. Fibulin binds to itself and to the carboxylterminal heparin-
binding region of fibronectin. J. Biol. Chem. 1992, 267:20120-25. 
48. Schwarzbauer JE, et al. Identification of the fibronectin sequences required for 
assembly of fibrillar matrix. J. Cell Biol. 1991, 113:1463-73. 
49. Aquirre KM, et al. Fibronectin self-association is mediated by complementary sites 
within the amino-terminal one-third of the molecule. J. Biol. Chem. 1994, 
269(45):27863-68. 
50. Yi M, et al. Antiangiogenic proteins require plasma fibronectin or vitronectin for in 
vivo activity. Proc. Natl. Acad. Sci. USA. 2003, 100:11435-38. 
  
 
 
        77 
51. Pang AL, et al. U 94 alters FN1 and ANGPTL4 gene expression and inhibits 
tumorigenesis of prostate cancer cell line PC3. Cancer cell international. 2005, 5:19 
1475-2867. 
52. Ye B, Cramer D W. Haptoglobin-  subunit as potential serum biomarker in ovarian 
cancer. Clinical cancer research 2003, 9:2904-11. 
53. Goncalves A, Esterni B. Prostoperative serum proteomic profiles may predict 
metastatic relapse in high-risk primary breast cancer patients receiving adjuvant 
chemotherapy. Oncogene 2006, 25:981-89. 
54. Sanders ME, Dias EC. Differentiating proteomic biomarkers in breast cancer by laser 
capture microdissection and MALDI  MS. J. Proteome Res. 2008, 7 (4): 1500–1507. 
55. Ehlermann P, Eggers K. Increased proinflammatory endothelial response to         
S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc 
Diabetol 2006, 5:1475-2840. 
56. Tolson JP, Flad T. Differential detection of S100A8 in transitional cell carcinoma of 
the bladder by pair wise tissue proteomic and immunohistochemical analysis. 
Proteomics 2003, 6(2): 697 – 708. 
 
 
 
 
 
 
 
 
CURRICULUM VITAE 
 
 
Guihong Qi 
 
 
Education 
Master of Science, Biotechnology (2008) 
Indiana University, Indianapolis, IN 
Thesis: “Biomarker Discovery in Early Stage Breast Cancer Using Proteomics 
Technologies” 
Graduate Certificate in Biotechnology (2007) 
Indiana University, Indianapolis, IN 
Bachelor of Science, Chemistry (1988) 
Harbin Normal University, Harbin, Heilongjiang, P.R.China 
 
Professional Experience 
  
Senior Research Associate, Monarch LifeSciences, LLC, Indianapolis, IN, 2004-present 
• Worked on two-dimensional gel electrophoresis (2DE) based on proteomics 
projects, including sample preparation,  protein assay, large format gradient and 
linear gels casting, iso-electric focusing, gel spots cutting and image analysis by 
using PDQuest software. 
• Prepped serum, cell lysate, tissue, etc. biological samples for protein identification 
and quantification, including protein extraction, precipitation, dialysis, high 
abundant protein removal using affinity technique, in-solution and in-gel 
enzymatic digestion.  
• Set up and maintained instruments (MALDI-TOF from Micromass, Q-TOF from 
Micromass, MALDI-TOF/TOF from Applied-Biosystems, LTQ from 
Thermofinnigan, spots cutter and Flour-S multi-imager from Bio-Rad) for 
proteins and peptides analysis including buffer preparation, calibration, tuning, 
cleaning and running. 
• Performed database search for analyzed proteins using ProFound, Mascot and 
SEQUEST. 
• Trained internal personnel and our clients. 
• Interpreted results and documenting work with our scientist and customers. 
 
Research Technician, Proteomics core facility, Department of Biochemistry and 
Molecular Biology, Indiana University, Indianapolis, IN, 2003-2004     
           
• Prepared and run 2DE samples including extraction, desalting, protein assay, iso-
electric focusing and SDS page. 
• Cast large format gradient and linear gels. 
• Scanned and analyzed 2DE images using PDQuest software. 
• Performed manual and robotic protein digestion.  
• Analyzed protein and peptide using MALDI-TOF. 
• Performed protein peptide mass fingerprint. 
• Generated data for our customers. 
 
Research Technician, Department of Biochemistry and Molecular Biology, Indiana 
University, Indianapolis, IN, 2001-2003 
 
• Synthesized peptide manually and by using ABI 431, 433-peptide synthesizer. 
• Purified peptide with preparative HPLC. 
• Characterized peptide by using analytical HPLC, TLC and Mass spectrometry.  
• Independently performed peptide synthesis procedure. 
• Recorded and monitored laboratory activities. 
 
Research Experience 
 
• Applied LC-MS/MS label free quantification technique in biomarker discovery 
and validation for pharmaceutical companies and academic clients. 
• Analyzed biological pathways and find the proteins network connections from the 
protein dataset using Pathway Studio™.  
 
Conferences Attended   
 
NCI Annual Meeting on Clinical Proteomic Technologies for Cancer, 2008 
• Poster session: “Quantitative Proteomic Analysis of Human Plasma Samples from 
Breast Cancer Patients Using an LC/MS-based Label-free Protein Quantification 
Platform” Guihong Qi, Jinsam You, Jong-Won Kim, Kerry Bemis and Mu Wang 
Biochemistry and Molecular Biology Research Day, Indian University, Indianapolis, IN, 
2008 
• Poster session: “Biomarker Discovery in Early Stage Breast Cancer Using 
Proteomics Technologies” Guihong Qi, Jinsam You, Kerry Bemis and Mu Wang 
The Indiana University School of Medicine biannual Dean’s Grand Rounds and 
Scientific Session, 2008 
• Poster session: “Biomarker Discovery in Early Stage Breast Cancer Using 
Proteomics Technologies” Guihong Qi, Jinsam You, Kerry Bemis and Mu Wang 
 
Publications  
 
Dawn P. G. Brown, Guihong Qi, Frank A. Witzmann, George W. Sledge Jr. , Mu Wang,  
“A comparative proteomic study to characterize the vinblastine resistance in human 
ovarian cancer cells”, Journal of Proteomics, 2007. 1(1): p.18-31 
 
 
 
 
 
